phthalazines - Ontology Report - Rat Genome Database

phthalazines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

Subscribe to Updates

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	phthalazines	go back to main search page
Accession:	CHEBI:38768	browse the term

Loading Annotations...

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

X

List All Objects | CSV Export | Add Objects | Clear

show annotations for term's descendants Sort by:
Rat (823 ) Mouse (829 ) Human (867 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (823)

(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B1

decreases activity
multiple interactions

ISO

zopolrestat results in decreased activity of AKR1B1 protein
[zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased abundance of Reactive Oxygen Species]; [zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased secretion of Dinoprostone]; [zopolrestat results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to Antigens, Plant

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

multiple interactions
decreases activity

ISO

zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde]
zopolrestat results in decreased activity of AKR1B10 protein; zopolrestat results in decreased activity of AKR1B10 protein mutant form

PMID:18325492 PMID:19028477

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:63,040,169...63,053,852

G

C-C motif chemokine ligand 4

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of CCL4 mRNA]

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of CCL5 mRNA]

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377

G

interleukin 10

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL10 mRNA]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL13 mRNA]

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL18 mRNA]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 4

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL4 mRNA]

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL5 mRNA]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL6 mRNA]
zopolrestat inhibits the reaction [Antigens, Plant results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

Janus kinase 2

multiple interactions

EXP

zopolrestat results in decreased phosphorylation of and results in decreased activity of JAK2 protein

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189

G

nitric oxide synthase 2

multiple interactions

ISO

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

signal transducer and activator of transcription 5A

multiple interactions

EXP

zopolrestat results in decreased phosphorylation of and results in decreased activity of STAT5A protein

NCBI chr10:86,285,859...86,310,187
Ensembl chr10:85,785,537...85,809,866

G

tumor necrosis factor

multiple interactions

ISO

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of TNF mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]

PMID:21334316 PMID:24021941

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity
multiple interactions

ISO

azelastine results in decreased activity of ABCB1 protein
azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

acetylcholinesterase

decreases activity

ISO

azelastine results in decreased activity of ACHE protein

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651

G

collagen type I alpha 1 chain

decreases expression

ISO

azelastine results in decreased expression of COL1A1 mRNA

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression

ISO

azelastine results in decreased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547

G

collagen type VI alpha 1 chain

decreases expression

ISO

azelastine results in decreased expression of COL6A1 mRNA

NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,957...11,924,597

G

histamine receptor H 1

affects binding

ISO

azelastine binds to HRH1 protein

NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:147,645,995...147,647,455

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

azelastine results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008

G

solute carrier family 22 member 2

multiple interactions

ISO

azelastine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268

Desmethylazelastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity
multiple interactions

ISO

desmethylazelastine results in decreased activity of ABCB1 protein
desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

renin

increases activity

ISO

Dihydralazine results in increased activity of REN protein

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:44,796,091...44,807,489

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ABCB5 mRNA

NCBI chr 6:145,978,860...146,075,776
Ensembl chr 6:139,835,949...139,932,830

G

acetyl-CoA acyltransferase 1A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAA1 mRNA

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:119,079,775...119,088,624

G

acyl-CoA dehydrogenase family, member 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAD9 mRNA

NCBI chr 2:120,871,329...120,894,306
Ensembl chr 2:118,943,174...118,966,547

G

acetyl-CoA acetyltransferase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAT2 mRNA

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:47,695,788...47,752,821

G

angiotensin I converting enzyme

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131

G

apoptotic chromatin condensation inducer 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACIN1 mRNA

NCBI chr15:32,072,121...32,117,004
Ensembl chr15:28,102,112...28,147,001

G

acyl-CoA thioesterase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ACOT2 mRNA

NCBI chr 6:109,341,426...109,352,818
Ensembl chr 6:103,611,544...103,619,245

G

actin, alpha 1, skeletal muscle

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]

NCBI chr19:68,781,168...68,784,194
Ensembl chr19:51,883,715...51,886,742

G

ADAM metallopeptidase with thrombospondin type 1 motif, 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADAMTS10 mRNA

NCBI chr 7:15,033,859...15,063,800
Ensembl chr 7:14,331,745...14,361,620

G

adhesion G protein-coupled receptor A3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADGRA3 mRNA

NCBI chr14:65,085,418...65,188,949
Ensembl chr14:60,874,715...60,976,332

G

adiponectin receptor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADIPOR1 mRNA

NCBI chr13:48,411,438...48,431,251
Ensembl chr13:45,859,533...45,879,241

G

adenylosuccinate lyase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADSL mRNA

NCBI chr 7:114,359,440...114,383,618
Ensembl chr 7:112,479,271...112,503,760

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AFG3L2 mRNA

NCBI chr18:63,224,163...63,269,000
Ensembl chr18:60,954,268...60,999,110

G

acylglycerol kinase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AGK mRNA

NCBI chr 4:70,081,550...70,160,642
Ensembl chr 4:69,114,269...69,193,934

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of AGPAT2 mRNA

NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:9,416,843...9,428,371

G

angiotensinogen

multiple interactions
decreases response to substance

EXP
ISO

Hydralazine affects the reaction [AGT protein results in increased abundance of Fatty Acids, Nonesterified]; Hydralazine affects the reaction [AGT protein results in increased abundance of Triglycerides]; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]; Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]
Hydralazine results in decreased susceptibility to AGT protein modified form

PMID:16344371 PMID:19109942 PMID:21289285

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977

G

aldo-keto reductase family 1 member A1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1A1 mRNA

NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1, member C2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1C2 mRNA

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:65,759,788...65,775,764

G

AKT serine/threonine kinase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKT2 mRNA

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:82,883,547...82,933,817

G

albumin

affects binding
multiple interactions

ISO

Hydralazine binds to [Acrolein binds to ALB protein]
Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA]

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 18 family, member A1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH18A1 mRNA

NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:239,375,669...239,407,890

G

aldehyde dehydrogenase 9 family, member A1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH9A1 mRNA

NCBI chr13:82,038,679...82,055,478
Ensembl chr13:79,505,695...79,540,568

G

arachidonate 15-lipoxygenase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ALOX15 mRNA

NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,060,412...55,068,874

G

anaphase promoting complex subunit 11

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANAPC11 mRNA

NCBI chr10:106,373,610...106,384,633

G

androgen regulated protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CST4 mRNA

NCBI chr 3:157,171,739...157,178,262
Ensembl chr 3:136,718,602...136,724,966

G

ankyrin-repeat and fibronectin type III domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKFN1 mRNA

NCBI chr10:74,711,284...75,099,954
Ensembl chr10:74,218,915...74,663,295

G

ankyrin repeat and KH domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA

NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024

G

ankyrin repeat and IBR domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKIB1 mRNA

NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781

G

ankyrin repeat domain 44

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKRD44 mRNA

NCBI chr 9:63,621,193...63,921,999
Ensembl chr 9:56,126,747...56,427,508

G

annexin A2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANXA2 mRNA

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658

G

acyloxyacyl hydrolase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of AOAH mRNA

NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148

G

amine oxidase, copper containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AOC1 mRNA

NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:77,812,260...77,831,840

G

APC regulator of WNT signaling pathway

decreases methylation

ISO

Hydralazine results in decreased methylation of APC promoter

NCBI chr18:26,138,382...26,196,021
Ensembl chr18:25,864,222...25,922,696

G

APC down-regulated 1 like

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of APCDD1L mRNA

NCBI chr 3:162,587,484...162,658,362
Ensembl chr 3:162,582,252...162,658,073

G

aquaporin 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of AQP10 mRNA

NCBI chr 2:177,699,717...177,704,620
Ensembl chr 2:175,403,263...175,406,815

G

archain 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARCN1 mRNA

NCBI chr 8:53,954,401...53,979,005
Ensembl chr 8:45,057,619...45,082,247

G

ARF GTPase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARF1 mRNA

NCBI chr10:44,497,543...44,513,994
Ensembl chr10:43,997,986...44,014,434

G

Rho GTPase activating protein 23

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP23 mRNA

NCBI chr10:82,891,021...82,993,230
Ensembl chr10:82,394,648...82,496,504

G

Rho GTPase activating protein 40

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP40 mRNA

NCBI chr 3:167,585,665...167,626,433
Ensembl chr 3:147,165,729...147,207,203

G

Rho GTPase activating protein 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP5 mRNA

NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:69,976,214...70,037,660

G

Rho guanine nucleotide exchange factor 12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

ariadne RBR E3 ubiquitin protein ligase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARIH2 mRNA

NCBI chr 8:118,175,267...118,234,425
Ensembl chr 8:109,296,738...109,355,852

G

ARF like GTPase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL2 mRNA

NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119

G

ARF like GTPase 6 interacting protein 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL6IP5 mRNA

NCBI chr 4:131,365,320...131,395,311
Ensembl chr 4:129,810,645...129,838,608

G

ADP-ribosyltransferase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ART4 mRNA

NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDEFL1 mRNA

NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASB7 mRNA

NCBI chr 1:120,222,835...120,267,411
Ensembl chr 1:120,222,745...120,267,282

G

acid sensing ion channel subunit family member 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASIC4 mRNA

NCBI chr 9:84,389,610...84,411,545
Ensembl chr 9:76,941,532...76,962,900

G

aspartate-beta-hydroxylase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASPH mRNA

NCBI chr 5:27,398,933...27,611,519
Ensembl chr 5:22,603,486...22,813,876

G

activating transcription factor 3

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF3 mRNA]

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF4 mRNA]

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATG10 mRNA

NCBI chr 2:23,843,695...24,133,459
Ensembl chr 2:22,108,426...22,398,233

G

ATPase 13A4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP13A4 mRNA

NCBI chr11:84,727,014...84,864,747
Ensembl chr11:71,226,161...71,359,933

G

ATP synthase F1 subunit epsilon

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5F1E mRNA

NCBI chr 3:183,677,270...183,680,172
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase membrane subunit c locus 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5MC3 mRNA

NCBI chr 3:79,218,014...79,220,664
Ensembl chr 3:58,810,535...58,814,279

G

ATP synthase membrane subunit e

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5ME mRNA

NCBI chr14:1,464,788...1,465,989
Ensembl chr14:1,319,868...1,321,013

G

ATP synthase peripheral stalk subunit F6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5PF mRNA

NCBI chr11:37,368,045...37,375,721
Ensembl chr11:23,881,592...23,889,119

G

ATPase H+ transporting accessory protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6AP1 mRNA

NCBI chr X:157,231,243...157,238,323
Ensembl chr X:152,079,865...152,087,034

G

ATPase H+ transporting V1 subunit B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1B1 mRNA

NCBI chr 4:117,781,444...117,800,103
Ensembl chr 4:116,223,799...116,242,475

G

ATPase H+ transporting V1 subunit C1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1C1 mRNA

NCBI chr 7:71,719,326...71,757,191
Ensembl chr 7:69,834,463...69,872,278

G

ataxin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN2 mRNA

NCBI chr12:40,413,657...40,509,895
Ensembl chr12:34,754,137...34,851,479

G

ataxin 7-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN7L1 mRNA

NCBI chr 6:49,759,876...49,982,323
Ensembl chr 6:49,759,883...49,982,320

G

B9 domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of B9D1 mRNA

NCBI chr10:46,685,410...46,698,580
Ensembl chr10:46,186,691...46,196,008

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BAD mRNA

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823

G

BAG cochaperone 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BAG1 mRNA

NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:56,068,494...56,081,075

G

branched chain ketoacid dehydrogenase kinase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BCKDK mRNA

NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:182,515,327...182,536,633

G

bolA family member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BOLA1 mRNA

NCBI chr 2:186,447,386...186,448,402
Ensembl chr 2:183,758,441...183,781,576

G

bisphosphoglycerate mutase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPGM mRNA

NCBI chr 4:64,106,809...64,135,749
Ensembl chr 4:63,140,018...63,168,581

G

BPI fold containing family B, member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPIFB2 mRNA

NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044

G

bromodomain PHD finger transcription factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPTF mRNA

NCBI chr10:92,480,007...92,582,485
Ensembl chr10:91,982,758...92,082,769

G

bromodomain containing 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of BRD8 mRNA

NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884

G

C1q and TNF related 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of C1QTNF5 mRNA

NCBI chr 8:53,347,754...53,349,912
Ensembl chr 8:44,451,154...44,453,074

G

complement C4A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of C4A mRNA

NCBI chr20:4,010,306...4,024,707
Ensembl chr20:4,005,731...4,020,080

G

similar to human chromosome 9 open reading frame 152

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of C9ORF152 mRNA

NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379

G

similar to human chromosome 3 open reading frame 62

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of C3ORF62 mRNA

NCBI chr 8:117,958,583...117,963,137
Ensembl chr 8:109,036,030...109,097,895

G

similar to human chromosome 6 open reading frame 132

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of C6ORF132 mRNA

NCBI chr 9:21,022,482...21,058,942
Ensembl chr 9:13,525,395...13,561,585

G

calcium voltage-gated channel auxiliary subunit gamma 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CACNG6 mRNA

NCBI chr 1:74,648,342...74,663,351
Ensembl chr 1:65,732,632...65,747,341

G

calcium modulating ligand

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CAMLG mRNA

NCBI chr17:8,997,868...9,009,140
Ensembl chr17:8,992,696...9,003,552

G

calnexin

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CANX mRNA

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:34,625,191...34,656,821

G

carbonic anhydrase 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CA7 mRNA

NCBI chr19:435,520...444,927
Ensembl chr19:429,075...438,467

G

carbonic anhydrase 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CA8 mRNA

NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:21,305,383...21,402,374

G

CAS1 domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CASD1 mRNA

NCBI chr 4:32,659,196...32,739,228
Ensembl chr 4:32,658,748...32,739,202

G

caspase 12

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased cleavage of CASP12 protein]

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:2,642,434...2,674,037

G

chromobox 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CBX7 mRNA

NCBI chr 7:113,341,030...113,358,716
Ensembl chr 7:111,460,656...111,477,973

G

coiled-coil domain containing 138

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC138 mRNA

NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376

G

coiled-coil domain containing 146

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CCDC146 mRNA

NCBI chr 4:13,662,766...13,811,619
Ensembl chr 4:13,662,766...13,811,608

G

coiled-coil domain containing 47

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC47 mRNA

NCBI chr10:91,630,101...91,648,626
Ensembl chr10:91,130,303...91,148,881

G

coiled-coil domain containing 82

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 22

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL22 mRNA

NCBI chr19:10,263,589...10,270,359
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 28

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL28 mRNA

NCBI chr 2:53,334,071...53,358,709
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231

G

CCM2 scaffold protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCM2 mRNA

NCBI chr14:85,632,338...85,678,016
Ensembl chr14:81,418,236...81,464,116

G

chaperonin containing TCP1 subunit 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT2 mRNA

NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:52,692,725...52,706,944

G

chaperonin containing TCP1 subunit 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT7 mRNA

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:117,989,232...118,006,580

G

Cd63 molecule

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CD63 mRNA

NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,325,103...1,399,178

G

cytidine and dCMP deaminase domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDADC1 mRNA

NCBI chr15:37,902,789...37,934,853
Ensembl chr15:33,723,435...33,755,576

G

cell division cycle 37, HSP90 cochaperone

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC37 mRNA

NCBI chr 8:27,954,292...27,966,935
Ensembl chr 8:19,671,938...19,690,809

G

cell division cycle 42

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC42 mRNA

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111

G

cyclin-dependent kinase 12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK12 mRNA

NCBI chr10:83,697,174...83,793,676
Ensembl chr10:83,201,211...83,280,888
Ensembl chr10:83,201,211...83,280,888

G

cyclin-dependent kinase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK4 mRNA

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

EXP

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

multiple interactions
decreases methylation

EXP
ISO

[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]
Hydralazine results in decreased methylation of CDKN2A promoter

PMID:15862127 PMID:18504326

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149

G

cerebellar degeneration-related protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDR2 mRNA

NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472

G

carboxyl ester lipase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CEL mRNA

NCBI chr 3:32,281,518...32,289,019
Ensembl chr 3:11,883,532...11,891,035

G

centromere protein N

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CENPN mRNA

NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012

G

ceramide synthase 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CERS5 mRNA

NCBI chr 7:132,738,834...132,776,920
Ensembl chr 7:130,859,990...130,897,947

G

cilia and flagella associated protein 300

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CFAP300 mRNA

NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807

G

coiled-coil-helix-coiled-coil-helix domain containing 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD10 mRNA

NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,842...12,732,763

G

coiled-coil-helix-coiled-coil-helix domain containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD2 mRNA

NCBI chr12:32,464,847...32,470,871
Ensembl chr12:26,828,736...26,834,755

G

chromodomain helicase DNA binding protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:127,190,059...127,300,502

G

charged multivesicular body protein 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHMP5 mRNA

NCBI chr 5:60,877,369...60,894,512
Ensembl chr 5:56,081,343...56,098,529

G

chimerin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709

G

cholinergic receptor nicotinic alpha 1 subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHRNA1 mRNA

NCBI chr 3:78,862,286...78,877,353
Ensembl chr 3:58,454,744...58,469,840

G

carbohydrate sulfotransferase 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHST13 mRNA

NCBI chr 4:124,381,226...124,395,143
Ensembl chr 4:122,824,022...122,838,019

G

calcium and integrin binding 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CIB1 mRNA

NCBI chr 1:143,587,591...143,593,153
Ensembl chr 1:134,178,331...134,213,423

G

cytoplasmic linker associated protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLASP2 mRNA

NCBI chr 8:122,555,532...122,736,934
Ensembl chr 8:113,677,284...113,858,731

G

chloride voltage-gated channel 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLCN5 mRNA

NCBI chr X:17,857,260...18,011,844
Ensembl chr X:15,185,451...15,334,264

G

citramalyl-CoA lyase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLYBL mRNA

NCBI chr15:105,690,283...105,912,347
Ensembl chr15:99,283,650...99,505,695

G

cyclin and CBS domain divalent metal cation transport mediator 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CNNM3 mRNA

NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740

G

cytochrome C oxidase assembly factor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,220,194...86,221,178

G

component of oligomeric golgi complex 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COG5 mRNA

NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009

G

collagen type I alpha 1 chain

decreases expression
decreases expression
multiple interactions

ISO
EXP

Hydralazine results in decreased expression of COL1A1 mRNA
hydralazine decreases expression of Col1a1 mRNA in liver
[Hydralazine co-treated with Valproic Acid] results in increased expression of COL1A1 mRNA

CTD
RGD

PMID:8941590 PMID:17183730 PMID:33315911

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624

G

collagen type IV alpha 6 chain

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

copper metabolism domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD1 mRNA

NCBI chr14:101,081,667...101,185,738
Ensembl chr14:96,880,463...96,984,501

G

COMM domain containing 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD6 mRNA

NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382

G

COPI coat complex subunit epsilon

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COPE mRNA

NCBI chr16:19,148,832...19,159,052
Ensembl chr16:19,114,871...19,128,907

G

COP9 signalosome subunit 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COPS4 mRNA

NCBI chr14:9,382,897...9,413,216
Ensembl chr14:9,078,576...9,108,887

G

coenzyme Q4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COQ4 mRNA

NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799

G

cytochrome c oxidase subunit 6B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COX6B1 mRNA

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001
Ensembl chr 5:85,875,109...85,884,001

G

cytochrome c oxidase subunit 7C

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of COX7C mRNA

NCBI chr 2:18,577,145...18,579,170
Ensembl chr 2:16,840,837...16,843,760

G

carnitine palmitoyltransferase 1A

multiple interactions

EXP

Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CREB5 mRNA

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:82,393,730...82,790,325

G

crystallin, beta A4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CRYBA4 mRNA

NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221

G

CCCTC-binding factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CTCF mRNA

NCBI chr19:50,431,478...50,481,013
Ensembl chr19:33,529,319...33,571,123

G

catenin delta 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CTNND1 mRNA

NCBI chr 3:90,090,025...90,141,247
Ensembl chr 3:69,683,313...69,734,516

G

cathepsin K

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA

NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:183,058,569...183,069,550

G

CUE domain containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CUEDC2 mRNA

NCBI chr 1:245,192,057...245,200,594
Ensembl chr 1:245,192,063...245,200,339

G

cullin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CUL1 mRNA

NCBI chr 4:77,551,781...77,634,210
Ensembl chr 4:76,551,983...76,627,980

G

cytochrome b5 reductase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R1 mRNA

NCBI chr13:48,401,061...48,407,466
Ensembl chr13:45,849,091...45,855,458

G

cytochrome b5 reductase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R3 mRNA

NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:114,306,685...114,324,298

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYFIP2 mRNA

NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO
EXP

Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO
EXP

Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily a, polypeptide 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA

NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 4, subfamily x, polypeptide 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP4X1 mRNA

NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779

G

dishevelled-binding antagonist of beta-catenin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DACT2 mRNA

NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096

G

differentiation antagonizing non-protein coding RNA

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DANCR mRNA

NCBI chr14:34,481,052...34,482,032

G

death associated protein kinase 1

decreases methylation
increases expression

ISO

Hydralazine results in decreased methylation of DAPK1 promoter
Hydralazine results in increased expression of DAPK1 mRNA

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,930,213...4,090,991

G

DBF4B-CDC7 kinase regulatory subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DBF4B mRNA

NCBI chr10:88,209,913...88,219,336

G

diazepam binding inhibitor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DBI mRNA

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:31,206,988...31,268,693

G

DDB1 and CUL4 associated factor 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCAF8 mRNA

NCBI chr13:87,141,940...87,199,859
Ensembl chr13:84,610,248...84,669,726

G

DNA cross-link repair 1C

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCLRE1C mRNA

NCBI chr17:79,684,988...79,718,399
Ensembl chr17:74,776,935...74,809,186

G

decapping mRNA 1A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCP1A mRNA

NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 mRNA]; Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

D-dopachrome tautomerase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121
Ensembl chr20:12,884,243...12,888,482

G

DEAD-box helicase 27

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX27 mRNA

NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372

G

DEAD-box helicase 46

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX46 mRNA

NCBI chr17:8,947,237...8,993,705
Ensembl chr17:8,944,454...8,988,439

G

dihydrolipoamide S-acetyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of DLAT mRNA

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

dynein, axonemal, assembly factor 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of DNAAF5 mRNA

NCBI chr12:20,567,482...20,606,600
Ensembl chr12:15,453,636...15,492,739

G

dynein axonemal heavy chain 14

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAH14 mRNA

NCBI chr13:93,322,653...93,540,706
Ensembl chr13:93,322,711...93,538,646

G

DnaJ heat shock protein family (Hsp40) member A3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJA3 mRNA

NCBI chr10:11,361,168...11,386,599
Ensembl chr10:10,854,732...10,880,161

G

DnaJ heat shock protein family (Hsp40) member C3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC3 mRNA

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:96,025,624...96,065,181

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC8 mRNA

NCBI chr 5:150,029,064...150,047,115
Ensembl chr 5:144,745,036...144,763,108

G

dynein heavy chain domain 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNHD1 mRNA

NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858

G

dpy-19 like C-mannosyltransferase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DPY19L3 mRNA

NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339

G

dopamine receptor D4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DRD4 mRNA

NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553

G

DNA replication and sister chromatid cohesion 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DSCC1 mRNA

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

dynein cytoplasmic 1 light intermediate chain 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNC1LI1 mRNA

NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:114,376,662...114,410,934

G

dynein light chain LC8-type 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNLL1 mRNA

NCBI chr12:46,945,291...46,976,867
Ensembl chr12:41,312,367...41,314,741

G

endothelin 1

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic translation elongation factor 1 delta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EEF1D mRNA

NCBI chr 7:109,462,645...109,478,021
Ensembl chr 7:107,581,930...107,608,799

G

EF hand domain family, member B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHB mRNA

NCBI chr 9:6,608,791...6,680,104
Ensembl chr 9:6,372,194...6,441,919

G

EF-hand domain family, member D2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHD2 mRNA

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

euchromatic histone lysine methyltransferase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EHMT2 mRNA

NCBI chr20:3,924,263...3,941,238
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 3, subunit L

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF3L mRNA

NCBI chr 7:112,522,222...112,544,063
Ensembl chr 7:110,627,107...110,663,614

G

eukaryotic translation initiation factor 4B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4B mRNA

NCBI chr 7:135,085,259...135,107,054

G

eukaryotic translation initiation factor 4 gamma, 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4G3 mRNA

NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:150,195,226...150,418,363

G

ETS transcription factor ELK3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA

NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:27,768,599...27,804,084

G

elongation factor for RNA polymerase II

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELL mRNA

NCBI chr16:18,877,751...18,925,449
Ensembl chr16:18,843,780...18,891,118

G

elongation factor for RNA polymerase II 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ELL3 mRNA

NCBI chr 3:128,866,755...128,870,896
Ensembl chr 3:108,410,448...108,417,132

G

elastin

multiple interactions

EXP

[Isoproterenol co-treated with Hydralazine] results in increased expression of ELN protein

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:21,968,544...22,011,928

G

elongin B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOB mRNA

NCBI chr10:13,353,413...13,358,484
Ensembl chr10:12,848,827...12,853,635

G

ELOVL fatty acid elongase 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOVL6 mRNA

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:218,063,804...218,171,186

G

epithelial membrane protein 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EMP3 mRNA

NCBI chr 1:105,525,086...105,528,370
Ensembl chr 1:96,388,652...96,391,988

G

endothelial PAS domain protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPAS1 mRNA

NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:7,790,647...7,871,228

G

enhancer of polycomb homolog 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPC1 mRNA

NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425

G

Eph receptor A8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPHA8 mRNA

NCBI chr 5:154,449,566...154,476,966
Ensembl chr 5:149,166,697...149,193,399

G

epsin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPN2 mRNA

NCBI chr10:46,697,238...46,759,128
Ensembl chr10:46,197,785...46,259,642

G

glutamyl-prolyl-tRNA synthetase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPRS1 mRNA

NCBI chr13:99,431,955...99,503,510
Ensembl chr13:96,901,575...96,971,966

G

endoplasmic reticulum lectin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ERLEC1 mRNA

NCBI chr14:108,856,661...108,894,511
Ensembl chr14:104,655,673...104,693,480

G

endoplasmic reticulum oxidoreductase 1 beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA

NCBI chr17:92,913,696...92,987,401
Ensembl chr17:85,929,618...86,003,398

G

estrogen receptor 1

decreases methylation
multiple interactions
increases expression

ISO

Hydralazine results in decreased methylation of ESR1 promoter
Hydralazine inhibits the reaction [3-methylquinoline results in increased activity of ESR1 protein]; Hydralazine inhibits the reaction [8-methylquinoline results in increased activity of ESR1 protein]
Hydralazine results in increased expression of ESR1 mRNA

PMID:15862127 PMID:30896932

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

enhancer trap locus 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA1217 mRNA

NCBI chr17:87,749,486...88,213,158
Ensembl chr17:82,495,041...83,304,715

G

exocyst complex component 3-like 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC3L2 mRNA

NCBI chr 1:88,241,784...88,273,352
Ensembl chr 1:79,112,506...79,145,465

G

exocyst complex component 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC7 mRNA

NCBI chr10:101,521,630...101,540,425
Ensembl chr10:101,520,927...101,540,561

G

F11 receptor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of F11R mRNA

NCBI chr13:86,406,229...86,429,819
Ensembl chr13:83,873,797...83,897,402

G

coagulation factor XII

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of F12 mRNA

NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,207,683...9,215,530

G

family with sequence similarity 120 member A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM120A mRNA

NCBI chr17:15,890,151...15,981,337
Ensembl chr17:15,684,233...15,774,964

G

family with sequence similarity 13, member B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM13B mRNA

NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587

G

family with sequence similarity 162, member A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA

NCBI chr11:78,186,260...78,215,186
Ensembl chr11:64,680,323...64,711,239

G

family with sequence similarity 163, member A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of FAM163A mRNA

NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049

G

family with sequence similarity 210, member B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM210B mRNA

NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397

G

family with sequence similarity 241 member B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM241B mRNA

NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
Ensembl chr 6:30,052,324...30,055,084

G

FAM3 metabolism regulating signaling molecule A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM3A mRNA

NCBI chr X:157,317,993...157,326,640
Ensembl chr X:152,165,535...152,175,362

G

family with sequence similarity 50, member A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM50A mRNA

NCBI chr X:157,246,533...157,253,650
Ensembl chr X:152,095,245...152,102,362

G

Fas ligand

multiple interactions

EXP
ISO

Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA]
Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215

G

fibrosin-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FBRSL1 mRNA

NCBI chr12:46,231,466...46,320,607
Ensembl chr12:46,231,495...46,320,357

G

F-box and WD repeat domain containing 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FBXW4 mRNA

NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163

G

farnesyl diphosphate synthase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FDPS mRNA

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:174,486,665...174,507,776

G

free fatty acid receptor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FFAR3 mRNA

NCBI chr 1:95,232,804...95,234,144
Ensembl chr 1:86,104,920...86,106,849

G

fragile histidine triad diadenosine triphosphatase

decreases methylation
increases expression

ISO

Hydralazine results in decreased methylation of FHIT promoter
Hydralazine results in increased expression of FHIT mRNA

NCBI chr15:16,365,401...17,872,901
Ensembl chr15:13,934,995...15,442,340

G

fission, mitochondrial 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FIS1 mRNA

NCBI chr12:25,345,239...25,360,135
Ensembl chr12:19,708,558...19,723,377

G

flotillin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FLOT1 mRNA

NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,917,137...2,927,978

G

Fms related receptor tyrosine kinase 1

multiple interactions

EXP

[Hydralazine co-treated with Hydrochlorothiazide] inhibits the reaction [Cyclosporine results in increased expression of FLT1 mRNA]

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626

G

Fos proto-oncogene, AP-1 transcription factor subunit

affects expression

EXP

Hydralazine affects the expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box P1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FOXP1 mRNA

NCBI chr 4:133,117,346...133,808,647
Ensembl chr 4:131,564,756...132,112,258

G

forkhead box P2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of FOXP2 mRNA

NCBI chr 4:44,099,848...44,677,700
Ensembl chr 4:43,133,912...43,711,683

G

forkhead box P3

increases expression

ISO

Hydralazine results in increased expression of FOXP3 protein

NCBI chr X:17,580,380...17,601,181
Ensembl chr X:14,908,494...14,923,838

G

follistatin

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FST mRNA

NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:46,123,439...46,130,571

G

follistatin-like 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FSTL5 mRNA

NCBI chr 2:160,857,989...161,526,589
Ensembl chr 2:160,856,291...161,526,589

G

ferritin heavy chain 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FTH1 mRNA

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:206,627,103...206,725,424

G

ferritin, heavy polypeptide-like 17, member A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FTHL17 mRNA

NCBI chr X:53,547,274...53,548,251
Ensembl chr X:49,595,718...49,596,266

G

FXYD domain-containing ion transport regulator 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of FXYD5 mRNA

NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:86,267,406...86,277,519

G

GABA type A receptor-associated protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GABARAP mRNA

NCBI chr10:55,213,465...55,216,787
Ensembl chr10:54,714,198...54,717,765

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

galanin-like peptide

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GALP mRNA

NCBI chr 1:76,717,110...76,741,056
Ensembl chr 1:67,684,025...67,702,269

G

guanidinoacetate N-methyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GAMT mRNA

NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:9,448,628...9,451,778

G

glucosidase II alpha subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GANAB mRNA

NCBI chr 1:215,222,918...215,242,808
Ensembl chr 1:205,793,895...205,813,695

G

glutamine amidotransferase class 1 domain containing 3A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GATD3 mRNA

NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,744...10,522,885

G

GDNF family receptor alpha 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

GDNF family receptor alpha 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA3 mRNA

NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105

G

gap junction protein, delta 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GJD4 mRNA

NCBI chr17:57,348,844...57,352,601
Ensembl chr17:57,349,877...57,352,446

G

galactosidase, alpha

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GLA mRNA

NCBI chr X:102,062,497...102,073,915
Ensembl chr X:97,768,996...97,780,664

G

glyceronephosphate O-acyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GNPAT mRNA

NCBI chr19:69,719,707...69,746,244
Ensembl chr19:52,822,319...52,852,361

G

golgin B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLGB1 mRNA

NCBI chr11:77,348,573...77,406,165
Ensembl chr11:63,843,986...63,900,770

G

golgi membrane protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLM2 mRNA

NCBI chr 3:108,827,017...108,896,207
Ensembl chr 3:108,827,047...108,896,207

G

glycoprotein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GP2 mRNA

NCBI chr 1:183,228,395...183,243,954
Ensembl chr 1:173,797,057...173,812,619

G

glycosylphosphatidylinositol anchor attachment 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of GPAA1 mRNA

NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:108,051,861...108,055,484

G

GC-rich promoter binding protein 1-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPBP1L1 mRNA

NCBI chr 5:130,009,768...130,050,636
Ensembl chr 5:130,023,137...130,050,459

G

G protein-coupled receptor 83

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPR83 mRNA

NCBI chr 8:19,974,995...19,985,483
Ensembl chr 8:11,693,540...11,704,028

G

G protein pathway suppressor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPS2 mRNA

NCBI chr10:55,136,043...55,139,106
Ensembl chr10:54,637,455...54,640,650

G

glutamic--pyruvic transaminase

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

GRB2-related adaptor protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRAP mRNA

NCBI chr10:46,798,423...46,851,524
Ensembl chr10:46,332,909...46,352,056

G

G protein-coupled receptor kinase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of GRK3 mRNA

NCBI chr12:49,285,228...49,395,803
Ensembl chr12:43,624,897...43,731,262

G

G protein-coupled receptor kinase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRK4 mRNA

NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693

G

glutamate-rich WD repeat containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRWD1 mRNA

NCBI chr 1:105,437,708...105,443,410
Ensembl chr 1:96,301,261...96,307,201

G

gelsolin

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GSN mRNA

NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:18,585,172...18,638,402

G

glutathione S-transferase pi 1

decreases methylation
increases expression

ISO

Hydralazine results in decreased methylation of GSTP1 promoter
Hydralazine results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GSTT2 mRNA

NCBI chr20:12,819,053...12,822,724
Ensembl chr20:12,819,170...12,823,288

G

guanylate kinase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of GUK1 mRNA

NCBI chr10:44,471,075...44,488,332
Ensembl chr10:43,971,509...43,980,107

G

H3.3 histone A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of H3-3A mRNA

NCBI chr13:95,065,085...95,076,695
Ensembl chr13:92,533,298...92,544,908

G

3-hydroxyanthranilate 3,4-dioxygenase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HAAO mRNA

NCBI chr 6:16,598,325...16,617,590
Ensembl chr 6:10,845,771...10,864,877

G

hemoglobin alpha, adult chain 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBA1 mRNA

NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,307,815...15,338,392
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin subunit beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBB mRNA

NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:158,120,200...158,252,012

G

hemoglobin subunit zeta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBZ mRNA

NCBI chr10:15,848,279...15,849,757
Ensembl chr10:15,343,831...15,345,312

G

host cell factor C1 regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HCFC1R1 mRNA

NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850

G

HDGF like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HDGFL1 mRNA

NCBI chr17:38,207,906...38,209,902

G

HEAT repeat containing 5B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HEATR5B mRNA

NCBI chr 6:21,995,558...22,075,582
Ensembl chr 6:16,243,461...16,323,435

G

heme binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

HEN methyltransferase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HENMT1 mRNA

NCBI chr 2:199,258,107...199,291,739
Ensembl chr 2:196,586,797...196,599,738

G

homeostatic iron regulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HFE mRNA

NCBI chr17:41,841,302...41,849,359
Ensembl chr17:41,413,451...41,421,502

G

HIG1 hypoxia inducible domain family, member 2A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HIGD2A mRNA

NCBI chr17:10,026,961...10,027,885
Ensembl chr17:10,021,859...10,022,796

G

histone H4 transcription factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINFP mRNA

NCBI chr 8:53,525,576...53,541,101
Ensembl chr 8:44,634,333...44,641,000

G

histidine triad nucleotide binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT1 mRNA

NCBI chr10:39,490,225...39,493,970
Ensembl chr 4:92,100,973...92,101,568

G

histidine triad nucleotide binding protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT2 mRNA

NCBI chr 5:62,700,383...62,702,638
Ensembl chr 5:57,904,614...57,907,097

G

hexokinase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HK1 mRNA

NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,230,486...30,332,131

G

3-hydroxy-3-methylglutaryl-CoA lyase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGCL mRNA

NCBI chr 5:153,461,738...153,475,552
Ensembl chr 5:148,178,252...148,192,068

G

HMG-box containing 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGXB4 mRNA

NCBI chr19:13,364,741...13,403,563
Ensembl chr19:13,364,807...13,403,563

G

heme oxygenase 1

multiple interactions

ISO

Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

HPS3, biogenesis of lysosomal organelles complex 2 subunit 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HPS3 mRNA

NCBI chr 2:104,413,618...104,455,091
Ensembl chr 2:102,484,574...102,526,047

G

heparanase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HPSE mRNA

NCBI chr14:9,200,971...9,241,377
Ensembl chr14:8,896,593...8,937,010

G

heat shock factor binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HSBP1 mRNA

NCBI chr19:64,309,703...64,314,035
Ensembl chr19:47,400,966...47,435,821

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ISO

Hydralazine inhibits the reaction [Ethanol results in increased expression of HSPA5 mRNA]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HSPA8 mRNA

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259

G

hydroxypyruvate isomerase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HYI mRNA

NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251

G

intercellular adhesion molecule 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

isoprenylcysteine carboxyl methyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ICMT mRNA

NCBI chr 5:168,084,487...168,097,519
Ensembl chr 5:162,804,368...162,811,128

G

isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IDH3G mRNA

NCBI chr X:156,666,573...156,675,482
Ensembl chr X:151,515,247...151,524,171

G

interferon induced transmembrane protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFITM2 mRNA

NCBI chr 1:205,481,168...205,482,348
Ensembl chr 1:196,051,537...196,052,741

G

interferon-related developmental regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFRD1 mRNA

NCBI chr 6:62,996,560...63,044,996
Ensembl chr 6:57,269,384...57,288,990

G

intraflagellar transport 22

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT22 mRNA

NCBI chr12:25,397,092...25,405,522
Ensembl chr12:19,761,790...19,768,809

G

intraflagellar transport 57

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT57 mRNA

NCBI chr11:64,528,349...64,593,545
Ensembl chr11:51,059,611...51,124,812

G

immunoglobulin binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IGBP1 mRNA

NCBI chr X:69,622,925...69,645,167
Ensembl chr X:65,582,821...65,606,049

G

insulin-like growth factor 2 mRNA binding protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IGF2BP2 mRNA

NCBI chr11:92,378,908...92,478,893
Ensembl chr11:78,874,414...78,974,377

G

interleukin 10

increases secretion

ISO

Hydralazine results in increased secretion of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 receptor accessory protein-like 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IL1RAPL2 mRNA

NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753

G

interleukin 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of IL3 mRNA

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

decreases secretion
increases expression

ISO

Hydralazine results in decreased secretion of IL6 protein
Hydralazine results in increased expression of IL6 protein

PMID:16612254 PMID:19575532

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

innate immunity activator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of INAVA mRNA

NCBI chr13:50,218,149...50,238,430
Ensembl chr13:47,666,447...47,686,729

G

INO80 complex subunit E

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of INO80E mRNA

NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469

G

interferon regulatory factor 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:196,367,361...196,370,832

G

iroquois homeobox 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA

NCBI chr19:31,384,803...31,388,241
Ensembl chr19:15,211,878...15,215,317

G

iron-sulfur cluster assembly 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ISCA2 mRNA

NCBI chr 6:104,418,509...104,420,019
Ensembl chr 6:104,418,454...104,420,045
Ensembl chr14:104,418,454...104,420,045

G

integrin subunit alpha M

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ITGAM mRNA

NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503

G

intersectin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN1 mRNA

NCBI chr11:44,464,515...44,646,598
Ensembl chr11:30,978,590...31,160,645

G

intersectin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN2 mRNA

NCBI chr 6:33,336,086...33,446,818
Ensembl chr 6:27,600,406...27,727,124

G

jumonji and AT-rich interaction domain containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA

NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,777,266...19,955,690

G

jumonji domain containing 1C

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of JMJD1C mRNA

NCBI chr20:21,330,990...21,508,580
Ensembl chr20:21,332,147...21,463,122

G

KN motif and ankyrin repeat domains 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK1 mRNA

NCBI chr 1:232,381,720...232,500,834
Ensembl chr 1:222,877,622...223,074,514

G

KN motif and ankyrin repeat domains 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK4 mRNA

NCBI chr 5:118,516,994...118,581,024
Ensembl chr 5:113,402,468...113,465,555

G

potassium voltage-gated channel subfamily A member 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of KCNA7 mRNA

NCBI chr 1:105,022,549...105,028,041
Ensembl chr 1:95,886,073...95,891,565

G

KDEL endoplasmic reticulum protein retention receptor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KDELR3 mRNA

NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:111,079,218...111,101,600

G

KIAA0586 homolog

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA0586 mRNA

NCBI chr 6:89,622,711...89,725,951
Ensembl chr 6:89,623,699...89,725,962

G

KLF transcription factor 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KLF6 mRNA

NCBI chr17:69,449,483...69,458,478
Ensembl chr17:64,531,463...64,588,570

G

kelch-like family member 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of KLHL9 mRNA

NCBI chr 5:108,449,492...108,453,676

G

keratin 17

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of KRT17 mRNA

NCBI chr10:85,679,068...85,683,792
Ensembl chr10:85,178,675...85,183,392

G

LIM and SH3 protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LASP1 mRNA

NCBI chr10:83,290,820...83,331,989
Ensembl chr10:82,795,137...82,943,292

G

lymphoid enhancer binding factor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LEF1 mRNA

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794

G

galectin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:110,481,392...110,488,345

G

galectin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS2 mRNA

NCBI chr 7:112,283,630...112,290,228
Ensembl chr 7:110,403,173...110,404,802

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGR4 mRNA

NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:96,447,858...96,548,899

G

LHFPL tetraspan subfamily member 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LHFPL5 mRNA

NCBI chr20:6,634,058...6,644,264
Ensembl chr20:6,632,362...6,642,532

G

lin-37 DREAM MuvB core complex component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LIN37 mRNA

NCBI chr 1:85,809,065...85,813,235
Ensembl chr 1:85,809,074...85,812,991

G

epididymal secretory protein E3-beta-like

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of EDDM3A mRNA

NCBI chr15:26,859,514...26,860,154
Ensembl chr15:24,386,192...24,386,623

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPCAT4 mRNA

NCBI chr 3:119,499,128...119,507,275
Ensembl chr 3:99,044,729...99,052,875

G

lysophosphatidylglycerol acyltransferase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPGAT1 mRNA

NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333

G

lipin 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPIN3 mRNA

NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327

G

LIM domain containing preferred translocation partner in lipoma

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPP mRNA

NCBI chr11:89,292,060...89,933,973
Ensembl chr11:75,797,078...76,422,597

G

leucine rich repeat and fibronectin type III domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRFN1 mRNA

NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449

G

LDL receptor related protein 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRP10 mRNA

NCBI chr15:31,891,358...31,897,530
Ensembl chr15:27,920,259...27,927,505

G

leucine rich repeat containing 40

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA

NCBI chr 2:247,101,518...247,131,061
Ensembl chr 2:247,101,500...247,131,059

G

leucine rich repeat containing 8 VRAC subunit E

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC8E mRNA

NCBI chr12:7,376,103...7,387,250
Ensembl chr12:2,578,315...2,589,412

G

LUC7-like 3 pre-mRNA splicing factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of CROP mRNA

NCBI chr10:79,737,457...79,773,478
Ensembl chr10:79,240,563...79,276,538

G

lymphocyte antigen 86

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of LY86 mRNA

NCBI chr17:27,621,313...27,705,336
Ensembl chr17:27,415,830...27,487,260

G

monoamine oxidase A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAOA mRNA

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase kinase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAP2K3 mRNA

NCBI chr10:46,107,639...46,128,986
Ensembl chr10:45,607,163...45,629,492

G

mitogen activated protein kinase 1

multiple interactions

EXP

Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

EXP

Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

microtubule affinity regulating kinase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MARK3 mRNA

NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAS1 mRNA

NCBI chr 1:50,428,064...50,459,537
Ensembl chr 1:47,880,309...47,911,709

G

methyl-CpG binding domain protein 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MBD6 mRNA

NCBI chr 7:64,992,877...65,001,274
Ensembl chr 7:63,107,562...63,113,274

G

membrane bound O-acyltransferase domain containing 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MBOAT7 mRNA

NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538

G

malic enzyme 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ME2 mRNA

NCBI chr18:69,626,073...69,676,218
Ensembl chr18:67,355,795...67,400,987

G

mediator complex subunit 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MED8 mRNA

NCBI chr 5:137,234,028...137,234,912
Ensembl chr 5:131,943,982...131,950,305

G

methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL3 mRNA

NCBI chr15:27,476,659...27,491,134
Ensembl chr15:25,003,172...25,014,041

G

methyltransferase 6, tRNA N3-cytidine

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL6 mRNA

NCBI chr16:6,667,971...6,705,385
Ensembl chr16:6,583,465...6,698,975

G

major facilitator superfamily domain containing 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MFSD5 mRNA

NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396

G

alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MGAT1 mRNA

NCBI chr10:33,563,642...33,582,718
Ensembl chr10:33,561,388...33,591,503

G

O-6-methylguanine-DNA methyltransferase

decreases methylation
increases expression

ISO

Hydralazine results in decreased methylation of MGMT promoter
Hydralazine results in increased expression of MGMT mRNA

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:191,710,930...191,937,756

G

matrix Gla protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MGP mRNA

NCBI chr 4:171,497,472...171,500,888
Ensembl chr 4:169,766,279...169,769,667

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MICAL3 mRNA

NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590

G

mitochondrial contact site and cristae organizing system subunit 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MICOS13 mRNA

NCBI chr 9:1,439,841...1,441,782
Ensembl chr 9:1,439,058...1,442,076

G

MIS12 kinetochore complex component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MIS12 mRNA

NCBI chr10:56,238,317...56,246,491
Ensembl chr10:55,739,564...55,751,068

G

MKS transition zone complex subunit 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MKS1 mRNA

NCBI chr10:72,655,921...72,667,007
Ensembl chr10:72,655,921...72,666,655

G

MLLT10, histone lysine methyltransferase DOT1L cofactor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MLLT10 mRNA

NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345

G

metabolism of cobalamin associated B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMAB mRNA

NCBI chr12:47,819,757...47,833,127
Ensembl chr12:42,159,089...42,172,490

G

membrane metallo-endopeptidase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MME mRNA

NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP10 mRNA

NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 25

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP25 mRNA

NCBI chr10:13,164,974...13,180,503
Ensembl chr10:12,661,208...12,675,871

G

mercaptopyruvate sulfurtransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MPST mRNA

NCBI chr 7:111,836,079...111,843,651
Ensembl chr 7:109,955,675...109,963,141

G

MRN complex interacting protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRNIP mRNA

NCBI chr10:34,501,359...34,525,474
Ensembl chr10:34,501,384...34,525,469

G

mitochondrial ribosomal protein L11

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL11 mRNA

NCBI chr 1:211,693,807...211,696,667
Ensembl chr 1:202,264,471...202,267,756

G

mitochondrial ribosomal protein L39

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL39 mRNA

NCBI chr11:37,266,116...37,281,612
Ensembl chr11:23,779,662...23,795,125

G

mitochondrial ribosomal protein L45

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL45 mRNA

NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474

G

mitochondrial ribosomal protein L53

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL53 mRNA

NCBI chr 4:117,173,043...117,173,933

G

mitochondrial ribosomal protein S12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS12 mRNA

NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780

G

mitochondrial ribosomal protein S18A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS18A mRNA

NCBI chr 9:22,350,887...22,367,380
Ensembl chr 9:14,853,291...14,869,835

G

mitochondrial ribosomal protein S24

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS24 mRNA

NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871

G

mitochondrial ribosomal protein S5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS5 mRNA

NCBI chr 3:135,274,333...135,290,577
Ensembl chr 3:114,821,046...114,837,291

G

mitochondrial ribosome recycling factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRRF mRNA

NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908

G

metastasis associated 1 family, member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MTA3 mRNA

NCBI chr 6:16,619,575...16,739,732
Ensembl chr 6:10,867,011...10,986,883

G

myotubularin related protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MTMR4 mRNA

NCBI chr10:72,890,665...72,913,598
Ensembl chr10:72,392,551...72,416,342

G

mucin 1, cell surface associated

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MUC1 mRNA

NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:174,635,995...174,640,733

G

MYB proto-oncogene like 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA

NCBI chr 3:172,124,765...172,153,221
Ensembl chr 3:151,705,288...151,733,708

G

MYC binding protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:79,937,354...80,175,498

G

myosin heavy chain 7

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:28,446,550...28,468,217

G

myosin light chain 6B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYL6B mRNA

NCBI chr X:40,572,012...40,572,991

G

myomesin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOM1 mRNA

NCBI chr 9:118,362,547...118,485,954
Ensembl chr 9:110,915,943...111,039,344

G

myotilin

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOT mRNA

NCBI chr18:36,956,119...36,975,728
Ensembl chr18:36,705,314...36,724,841

G

N(alpha)-acetyltransferase 10, NatA catalytic subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA10 mRNA

NCBI chr X:156,807,378...156,812,632
Ensembl chr X:151,656,056...151,661,252

G

N(alpha)-acetyltransferase 38, NatC auxiliary subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA38 mRNA

NCBI chr10:54,588,304...54,617,715
Ensembl chr10:54,117,163...54,119,494

G

sodium leak channel, non-selective

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA

NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001

G

NALCN channel auxiliary factor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NALF2 mRNA

NCBI chr X:64,925,100...64,951,074
Ensembl chr X:64,925,051...64,951,077

G

nicotinamide phosphoribosyltransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NAMPT mRNA

NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:49,424,332...49,462,100

G

nucleosome assembly protein 1-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAP1L1 mRNA

NCBI chr 7:48,819,464...48,844,108
Ensembl chr 7:46,933,356...46,956,593

G

N-acetyltransferase 2

affects metabolic processing
increases acetylation

ISO

NAT2 protein affects the metabolism of Hydralazine
NAT2 protein results in increased acetylation of Hydralazine

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520

G

neurobeachin-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NBEAL1 mRNA

NCBI chr 9:69,069,326...69,237,932
Ensembl chr 9:61,575,356...61,736,750

G

NBR1, autophagy cargo receptor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NBR1 mRNA

NCBI chr10:86,978,024...87,006,664
Ensembl chr10:86,478,290...86,506,412

G

neutrophil cytosolic factor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCF1 mRNA

NCBI chr12:28,121,816...28,131,080
Ensembl chr12:22,485,451...22,494,646

G

nuclear receptor coactivator 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOA4 mRNA

NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

nuclear receptor co-repressor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOR1 mRNA

NCBI chr10:47,498,852...47,641,612
Ensembl chr10:46,999,536...47,141,032

G

natural cytotoxicity triggering receptor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NCR1 mRNA

NCBI chr 1:78,657,409...78,665,255
Ensembl chr 1:69,616,601...69,660,558

G

NADH:ubiquinone oxidoreductase subunit A1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA1 mRNA

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA13 mRNA

NCBI chr16:19,560,526...19,567,500
Ensembl chr16:19,526,565...19,535,726
Ensembl chr 7:19,526,565...19,535,726

G

NADH:ubiquinone oxidoreductase subunit A3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA3 mRNA

NCBI chr 1:74,512,928...74,515,558
Ensembl chr 1:65,597,578...65,600,235

G

NADH:ubiquinone oxidoreductase subunit A5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA5 mRNA

NCBI chr 4:53,962,877...53,971,235
Ensembl chr 4:52,995,546...53,005,598
Ensembl chr 5:52,995,546...53,005,598

G

NADH:ubiquinone oxidoreductase subunit A6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA6 mRNA

NCBI chr 7:115,746,460...115,750,317
Ensembl chr 7:113,866,382...113,870,239

G

NADH:ubiquinone oxidoreductase complex assembly factor 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFAF6 mRNA

NCBI chr 5:24,147,712...24,171,981
Ensembl chr 5:24,147,735...24,171,951

G

NADH:ubiquinone oxidoreductase subunit B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB1 mRNA

NCBI chr 6:121,115,649...121,124,055

G

NADH:ubiquinone oxidoreductase subunit B10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB10 mRNA

NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442

G

NADH:ubiquinone oxidoreductase subunit B2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB2 mRNA

NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
Ensembl chr 4:46,536,062...46,536,851

G

NADH:ubiquinone oxidoreductase subunit S5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFS5 mRNA

NCBI chr 5:141,258,828...141,264,552
Ensembl chr 5:135,974,034...135,979,603
Ensembl chr14:135,974,034...135,979,603
Ensembl chr 2:135,974,034...135,979,603

G

NEDD1 gamma-tubulin ring complex targeting factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NEDD1 mRNA

NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486

G

neuroepithelial cell transforming 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NET1 mRNA

NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441

G

neurofibromin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NF1 mRNA

NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,306,301...64,536,658

G

nuclear factor of activated T-cells 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NFATC2 mRNA

NCBI chr 3:177,615,189...177,747,493
Ensembl chr 3:157,198,872...157,328,325

G

NHL repeat containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NHLRC2 mRNA

NCBI chr 1:265,594,915...265,655,647
Ensembl chr 1:255,589,742...255,651,408

G

NHS actin remodeling regulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NHS mRNA

NCBI chr X:36,185,067...36,524,711
Ensembl chr X:32,552,026...32,889,992

G

NMD3 ribosome export adaptor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NMD3 mRNA

NCBI chr 2:156,285,773...156,348,394
Ensembl chr 2:154,013,020...154,039,259

G

NME/NM23 nucleoside diphosphate kinase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:78,906,083...78,916,408

G

nucleotide-binding oligomerization domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NOD1 mRNA

NCBI chr 4:85,391,142...85,442,281
Ensembl chr 4:84,060,880...84,111,404

G

nitric oxide synthase 1

increases expression

EXP

Hydralazine results in increased expression of NOS1 mRNA

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:38,626,714...38,710,945

G

NOVA alternative splicing regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NOVA1 mRNA

NCBI chr 6:69,506,983...69,632,437
Ensembl chr 6:63,783,489...63,906,289

G

neuronal PAS domain protein 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPAS3 mRNA

NCBI chr 6:76,438,064...77,263,185
Ensembl chr 6:70,703,170...71,524,884

G

neural proliferation, differentiation and control, 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPDC1 mRNA

NCBI chr 3:28,618,601...28,624,591
Ensembl chr 3:8,213,663...8,226,866

G

nephrocystin 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPHP4 mRNA

NCBI chr 5:162,986,157...163,073,708
Ensembl chr 5:162,988,370...163,073,706

G

natriuretic peptide B

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168

G

natriuretic peptide receptor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPR1 mRNA

NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR1H3 mRNA

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 2, group C, member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR2C2 mRNA

NCBI chr 4:126,167,350...126,223,942
Ensembl chr 4:124,608,960...124,661,902

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR3C1 mRNA

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375

G

neuronal regeneration related protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NREP mRNA

NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,017,083...25,046,591

G

neurexin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NRXN2 mRNA

NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:150,775,080...150,807,142

G

NSFL1 cofactor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSFL1C mRNA

NCBI chr 3:160,438,708...160,463,261
Ensembl chr 3:139,978,301...140,002,870

G

NOP2/Sun RNA methyltransferase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSUN4 mRNA

NCBI chr 5:134,749,024...134,773,630
Ensembl chr 5:129,512,307...129,532,423
Ensembl chr 5:129,512,307...129,532,423

G

N-terminal asparagine amidase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NTAN1 mRNA

NCBI chr10:2,111,090...2,126,119

G

neurotensin receptor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NTSR2 mRNA

NCBI chr 6:45,153,095...45,159,783
Ensembl chr 6:39,424,324...39,431,014

G

nuclear distribution C, dynein complex regulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUDC mRNA

NCBI chr 5:151,041,878...151,055,260
Ensembl chr 5:145,758,002...145,771,425

G

nudix hydrolase 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NUDT7 mRNA

NCBI chr19:59,034,808...59,049,148
Ensembl chr19:42,125,711...42,151,081

G

NUMB, endocytic adaptor protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUMB mRNA

NCBI chr 6:109,162,499...109,284,527
Ensembl chr 6:103,431,400...103,553,354

G

nucleoporin 153

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUP153 mRNA

NCBI chr17:18,178,434...18,231,109
Ensembl chr17:17,972,217...18,024,876

G

nuclear protein 1, transcriptional regulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:181,213,368...181,215,281

G

neurexophilin 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of NXPH3 mRNA

NCBI chr10:80,953,080...80,956,746
Ensembl chr10:80,455,429...80,462,415

G

ornithine decarboxylase antizyme 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OAZ1 mRNA

NCBI chr 7:9,534,530...9,536,990
Ensembl chr 7:8,883,851...8,886,310

G

obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OBSCN mRNA

NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723

G

OCIA domain containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OCIAD2 mRNA

NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265

G

orofacial cleft 1 candidate 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of OFCC1 mRNA

NCBI chr17:24,506,919...24,813,225
Ensembl chr17:24,539,047...24,811,079

G

O-GlcNAcase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGA mRNA

NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:244,598,292...244,634,359

G

8-oxoguanine DNA glycosylase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGG1 mRNA

NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:146,474,750...146,484,766

G

O-linked N-acetylglucosamine (GlcNAc) transferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGT mRNA

NCBI chr X:70,811,317...70,856,123
Ensembl chr X:66,771,349...66,816,146

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OPA1 mRNA

NCBI chr11:84,612,943...84,690,025
Ensembl chr11:71,109,873...71,185,109

G

opioid receptor, delta 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of OPRD1 mRNA

NCBI chr 5:149,590,244...149,624,999
Ensembl chr 5:144,306,188...144,340,960

G

olfactory receptor family 9 subfamily I member 1B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of OR9I1 mRNA

NCBI chr 1:211,096,191...211,097,141
Ensembl chr 1:211,090,402...211,097,815

G

purinergic receptor P2X 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of P2RX3 mRNA

NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:70,080,851...70,125,178

G

poly(A) binding protein cytoplasmic 1 like 2B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PABPC1L2B mRNA

G

platelet-activating factor acetylhydrolase 1b, catalytic subunit 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PAFAH1B3 mRNA

NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893

G

Parkinsonism associated deglycase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARK7 mRNA

NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:161,353,719...161,376,970

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase family, member 14

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP14 mRNA

NCBI chr11:78,408,134...78,440,201
Ensembl chr11:64,902,785...64,934,916

G

PAS domain containing repressor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PASD1 mRNA

NCBI chr X:149,617,933...149,639,214
Ensembl chr X:149,620,972...149,638,675

G

PBX homeobox 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PBX2 mRNA

NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425

G

pterin-4 alpha-carbinolamine dehydratase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCBD1 mRNA

NCBI chr20:29,573,362...29,587,181
Ensembl chr20:28,953,864...29,044,292
Ensembl chr20:28,953,864...29,044,292

G

propionyl-CoA carboxylase subunit beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCCB mRNA

NCBI chr 8:110,470,197...110,520,222
Ensembl chr 8:101,590,737...101,641,234

G

protocadherin related 15

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCDH15 mRNA

NCBI chr20:13,996,383...15,495,206
Ensembl chr20:13,963,565...15,494,719

G

proliferating cell nuclear antigen

multiple interactions

EXP

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

platelet derived growth factor receptor beta

decreases expression

EXP

hydralazine decreases expression of Pdgfrb protein in liver

RGD

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843

G

phosphatidylethanolamine binding protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PEBP4 mRNA

NCBI chr15:44,920,946...45,134,188
Ensembl chr15:44,921,886...45,134,191

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PFKFB4 mRNA

NCBI chr 8:118,522,371...118,565,478
Ensembl chr 8:109,643,937...109,685,634

G

profilin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PFN1 mRNA

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,365,262...55,527,631

G

phosphoglycerate mutase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PGAM2 mRNA

NCBI chr14:84,895,763...84,897,874
Ensembl chr14:80,681,776...80,683,940

G

phosphoglucomutase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PGM1 mRNA

NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:114,595,293...114,654,728

G

prohibitin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHB1 mRNA

NCBI chr10:81,102,043...81,114,815
Ensembl chr10:80,605,251...80,618,042

G

polyhomeotic homolog 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of PHC1 mRNA

NCBI chr 4:157,182,348...157,205,504
Ensembl chr 4:155,510,274...155,533,959

G

polyhomeotic homolog 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHC2 mRNA

NCBI chr 5:141,000,604...141,099,268
Ensembl chr 5:141,050,842...141,099,268

G

PHD finger protein 24

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHF24 mRNA

NCBI chr 5:61,939,261...61,966,879
Ensembl chr 5:57,142,632...57,168,497

G

phosphatidylinositol glycan anchor biosynthesis, class S

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PIGS mRNA

NCBI chr10:63,222,611...63,237,190
Ensembl chr10:63,222,572...63,237,187

G

prolactin induced protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PIP mRNA

NCBI chr 4:71,754,265...71,758,559
Ensembl chr 4:70,787,627...70,791,921

G

phospholipase C, gamma 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLCG1 mRNA

NCBI chr 3:169,805,299...169,836,040
Ensembl chr 3:149,385,587...149,416,330

G

pleiotropic regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLRG1 mRNA

NCBI chr 2:170,706,188...170,722,519
Ensembl chr 2:168,408,124...168,424,522

G

plexin domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLXDC1 mRNA

NCBI chr10:82,922,499...82,982,124
Ensembl chr10:82,922,508...82,982,130

G

phosphomannomutase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PMM2 mRNA

NCBI chr10:7,468,371...7,489,574
Ensembl chr10:6,961,709...6,983,098

G

phosphomevalonate kinase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PMVK mRNA

NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:174,876,657...174,886,364

G

DNA polymerase epsilon 4, accessory subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLE4 mRNA

NCBI chr 4:116,723,040...116,728,873
Ensembl chr 4:115,165,285...115,171,097

G

RNA polymerase I subunit H, antisense

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR1HASP mRNA

NCBI chr 9:23,596,073...23,597,239
Ensembl chr 9:16,098,624...16,099,790

G

RNA polymerase II, I and III subunit L

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR2L mRNA

NCBI chr 1:205,999,607...206,001,615
Ensembl chr19:8,335,702...8,335,905

G

POP5 homolog, ribonuclease P/MRP subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of POP5 mRNA

NCBI chr12:47,037,451...47,045,778
Ensembl chr12:41,376,755...41,381,336

G

peptidylprolyl isomerase like 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPIL4 mRNA

NCBI chr 1:2,273,582...2,305,639
Ensembl chr 1:2,273,609...2,305,632

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R12A mRNA

NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory subunit 9A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R9A mRNA

NCBI chr 4:33,936,949...34,258,927
Ensembl chr 4:33,024,450...33,286,907

G

protein phosphatase 2 scaffold subunit A beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP2R1B mRNA

NCBI chr 8:60,092,540...60,125,512
Ensembl chr 8:51,186,717...51,228,485

G

proline-rich protein BstNI subfamily 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRB3 mRNA

NCBI chr 4:165,564,424...165,569,229
Ensembl chr 4:165,564,424...165,569,227

G

PRKCSH beta subunit of glucosidase II

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKCSH mRNA

NCBI chr 8:28,810,836...28,822,503
Ensembl chr 8:20,534,880...20,546,492

G

protein kinase cGMP-dependent 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKG1 mRNA

NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:228,408,947...229,639,080

G

prominin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PROM2 mRNA

NCBI chr 3:135,200,944...135,215,130
Ensembl chr 3:114,747,654...114,761,787

G

pre-mRNA processing factor 18

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRPF18 mRNA

NCBI chr17:78,539,004...78,570,483
Ensembl chr17:73,630,571...73,690,979

G

proline rich 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRR13 mRNA

NCBI chr 7:135,471,040...135,474,344
Ensembl chr 7:133,592,490...133,601,005

G

phosphoribosyl transferase domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRTFDC1 mRNA

NCBI chr17:88,457,872...88,563,109
Ensembl chr17:83,548,803...83,655,179

G

pleckstrin and Sec7 domain containing 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSD3 mRNA

NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547

G

proteasome 20S subunit alpha 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA2 mRNA

NCBI chr17:55,250,054...55,260,441
Ensembl chr17:50,551,924...50,564,938

G

proteasome 20S subunit alpha 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA4 mRNA

NCBI chr 8:64,236,520...64,243,980
Ensembl chr 8:55,340,386...55,347,890

G

proteasome 20S subunit beta 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB1 mRNA

NCBI chr 1:65,115,770...65,136,516
Ensembl chr 1:56,420,618...56,463,560

G

proteasome 20S subunit beta 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB2 mRNA

NCBI chr 5:144,255,058...144,287,200
Ensembl chr 5:138,970,533...139,021,137

G

proteasome 20S subunit beta 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB3 mRNA

NCBI chr10:83,193,787...83,200,883
Ensembl chr10:82,697,425...82,704,521

G

proteasome 20S subunit beta 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB6 mRNA

NCBI chr10:55,737,852...55,740,218
Ensembl chr10:55,239,241...55,241,586

G

proteasome 20S subunit beta 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB9 mRNA

NCBI chr20:4,668,952...4,674,421
Ensembl chr20:4,666,046...4,672,512

G

proteasome 26S subunit, ATPase 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMC6 mRNA

NCBI chr15:21,022,314...21,043,785
Ensembl chr15:18,542,563...18,564,055

G

proteasome 26S subunit, non-ATPase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD1 mRNA

NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:86,709,947...86,785,211

G

proteasome 26S subunit, non-ATPase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of PSMD3 mRNA

NCBI chr10:84,139,249...84,151,879
Ensembl chr10:83,643,647...83,655,618

G

proteasome 26S subunit ubiquitin receptor, non-ATPase 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD4 mRNA

NCBI chr 2:185,287,941...185,297,238
Ensembl chr 2:182,598,934...182,608,194

G

proteasome 26S subunit, non-ATPase 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD8 mRNA

NCBI chr 1:93,601,857...93,608,689
Ensembl chr 1:84,474,378...84,481,209

G

proteasome assembly chaperone 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMG3 mRNA

NCBI chr12:14,809,440...14,812,357
Ensembl chr12:14,809,450...14,812,342

G

protein tyrosine kinase 2 beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTK2B mRNA

NCBI chr15:44,536,275...44,656,754
Ensembl chr15:40,360,723...40,481,282

G

prothymosin alpha

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTMA mRNA

NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, receptor type, J

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTPRJ mRNA

NCBI chr 3:96,861,785...97,017,702
Ensembl chr 3:76,405,927...76,562,260

G

poly-U binding splicing factor 60

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PUF60 mRNA

NCBI chr 7:109,663,490...109,674,443
Ensembl chr 7:107,782,770...107,794,531

G

pumilio RNA-binding family member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PUM1 mRNA

NCBI chr 5:148,120,712...148,238,468
Ensembl chr 5:142,837,127...142,954,039

G

PYD and CARD domain containing

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCARD mRNA

NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955

G

pyrroline-5-carboxylate reductase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCR3 mRNA

NCBI chr 7:109,484,263...109,489,554
Ensembl chr 7:107,581,930...107,608,799

G

RAB13, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB13 mRNA

NCBI chr 2:177,972,535...177,977,679
Ensembl chr 2:175,675,005...175,680,036

G

RAB1A, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB1A mRNA

NCBI chr14:98,623,582...98,648,766
Ensembl chr14:94,415,275...94,448,248

G

RAB30, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB30 mRNA

NCBI chr 1:156,216,137...156,310,778
Ensembl chr 1:146,803,714...146,892,181

G

RAB3A, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA

NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,684,188...18,688,336

G

RAB3D, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3D mRNA

NCBI chr 8:28,714,706...28,725,379
Ensembl chr 8:20,439,294...20,449,185

G

RAB6A, member RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB6A mRNA

NCBI chr 1:164,370,033...164,422,324
Ensembl chr 1:154,958,189...154,996,715

G

rabaptin, RAB GTPase binding effector protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RABEP2 mRNA

NCBI chr 1:190,433,501...190,457,241
Ensembl chr 1:181,010,305...181,026,648

G

RAB guanine nucleotide exchange factor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RABGEF1 mRNA

NCBI chr12:32,096,338...32,139,949
Ensembl chr12:26,460,175...26,503,744

G

RAD21 cohesin complex component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAD21 mRNA

NCBI chr 7:85,177,715...85,204,657
Ensembl chr 7:83,287,870...83,314,817

G

ral guanine nucleotide dissociation stimulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGDS mRNA

NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059

G

Ral GEF with PH domain and SH3 binding motif 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGPS1 mRNA

NCBI chr 3:36,831,029...37,067,659
Ensembl chr 3:16,433,742...16,669,972

G

receptor activity modifying protein 2

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]

NCBI chr10:86,689,148...86,690,956
Ensembl chr10:86,188,812...86,231,829

G

receptor activity modifying protein 3

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]

NCBI chr14:85,741,314...85,758,813
Ensembl chr14:81,527,385...81,544,902

G

RAP1A, member of RAS oncogene family

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAP1A mRNA

NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:193,208,635...193,286,501

G

retinoic acid receptor, beta

decreases methylation

ISO

Hydralazine results in decreased methylation of RARB promoter

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:8,406,492...9,051,288

G

RB transcriptional corepressor like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBL1 mRNA

NCBI chr 3:166,226,187...166,289,862
Ensembl chr 3:145,807,095...145,869,330

G

RNA binding motif protein 22

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM22 mRNA

NCBI chr18:56,283,807...56,294,615
Ensembl chr18:54,013,351...54,024,569

G

RNA binding motif protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM4 mRNA

NCBI chr 1:211,507,845...211,516,907
Ensembl chr 1:202,085,279...202,105,380

G

RNA terminal phosphate cyclase-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RCL1 mRNA

NCBI chr 1:236,238,078...236,282,597
Ensembl chr 1:226,824,534...226,902,315

G

receptor accessory protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of REEP4 mRNA

NCBI chr15:52,030,022...52,033,229
Ensembl chr15:45,619,941...45,623,526

G

regenerating family member 1 alpha

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of REG1A mRNA

NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

renin

multiple interactions
increases activity
increases expression

ISO
EXP

Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein]
Hydralazine results in increased activity of REN protein

PMID:231700 PMID:923630 PMID:2203898 PMID:2953239 PMID:3154321

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:44,796,091...44,807,489

G

retention in endoplasmic reticulum sorting receptor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RER1 mRNA

NCBI chr 5:170,916,643...170,929,073
Ensembl chr 5:165,634,300...165,646,750

G

regulatory factor X1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RFX1 mRNA

NCBI chr19:24,061,336...24,092,044
Ensembl chr19:24,061,336...24,092,044

G

regulator of G-protein signaling 7 binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS7BP mRNA

NCBI chr 2:37,867,698...37,965,587
Ensembl chr 2:36,139,201...36,231,505

G

regulator of G-protein signaling 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9 mRNA

NCBI chr10:94,696,556...94,770,387
Ensembl chr10:94,197,054...94,270,892

G

regulator of G protein signaling 9 binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9BP mRNA

NCBI chr 1:88,249,438...88,250,151
Ensembl chr 1:88,249,438...88,250,151

G

Ras and Rab interactor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIN3 mRNA

NCBI chr 6:127,196,648...127,305,821
Ensembl chr 6:121,431,339...121,540,957

G

Ras and Rab interactor-like

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RINL mRNA

NCBI chr 1:84,077,011...84,088,590
Ensembl chr 1:84,077,265...84,088,330

G

receptor interacting serine/threonine kinase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPK1 mRNA

NCBI chr17:31,044,983...31,077,167
Ensembl chr17:30,839,650...30,871,824

G

ripply transcriptional repressor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPPLY1 mRNA

NCBI chr X:103,436,731...103,440,904
Ensembl chr X:103,436,729...103,443,349

G

required for meiotic nuclear division 5 homolog B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RMND5B mRNA

NCBI chr10:36,382,212...36,394,801
Ensembl chr10:35,881,268...35,892,265

G

ring finger protein 152

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF152 mRNA

NCBI chr13:21,324,039...21,403,405
Ensembl chr13:21,323,824...21,403,113

G

ring finger protein 187

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF187 mRNA

NCBI chr10:44,209,080...44,214,979
Ensembl chr10:43,702,357...43,716,157

G

roundabout guidance receptor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ROBO2 mRNA

NCBI chr11:26,015,919...27,583,750
Ensembl chr11:12,528,951...13,041,536

G

reactive oxygen species modulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ROMO1 mRNA

NCBI chr 3:165,119,794...165,121,394
Ensembl chr 3:144,659,826...144,661,310

G

ribosomal protein L10A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL10A mRNA

NCBI chr20:6,390,533...6,393,091
Ensembl chr20:6,385,823...6,391,357
Ensembl chr 9:6,385,823...6,391,357

G

ribosomal protein L13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL13 mRNA

NCBI chr19:68,062,442...68,065,065
Ensembl chr19:51,153,924...51,163,014
Ensembl chr 3:51,153,924...51,163,014

G

ribosomal protein L17

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL17 mRNA

NCBI chr18:70,856,275...70,859,388
Ensembl chr18:68,581,098...68,584,253
Ensembl chr 3:68,581,098...68,584,253

G

ribosomal protein L18A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL18A mRNA

NCBI chr16:18,576,467...18,578,653
Ensembl chr16:18,542,566...18,545,546
Ensembl chr 1:18,542,566...18,545,546

G

ribosomal protein L23A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL23A mRNA

NCBI chr10:63,574,732...63,577,511
Ensembl chr10:63,076,066...63,079,346
Ensembl chr15:63,076,066...63,079,346

G

ribosomal protein L24

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL24 mRNA

NCBI chr11:58,122,997...58,128,405
Ensembl chr11:44,653,937...44,659,370

G

ribosomal protein L26

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL26 mRNA

NCBI chr10:54,109,692...54,112,822
Ensembl chr10:53,610,421...53,613,966

G

ribosomal protein L27

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL27 mRNA

NCBI chr10:86,875,758...86,879,457
Ensembl chr10:86,375,454...86,379,193

G

ribosomal protein L31

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL31 mRNA

NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:41,647,426...41,662,129
Ensembl chr 8:41,647,426...41,662,129

G

ribosomal protein L34

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL34 mRNA

NCBI chr 2:221,958,551...221,962,309
Ensembl chr 2:219,284,382...219,288,111
Ensembl chr17:219,284,382...219,288,111

G

ribosomal protein L36

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL36 mRNA

NCBI chr 9:1,529,117...1,534,534
Ensembl chr 6:98,809,534...98,809,897
Ensembl chr 5:98,809,534...98,809,897

G

ribosomal protein L37A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL37A mRNA

NCBI chr 9:74,298,843...74,300,926

G

ribosomal protein L39

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL39 mRNA

NCBI chr  X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr15:6,326,330...6,326,692
Ensembl chr20:6,326,330...6,326,692
Ensembl chr 7:6,326,330...6,326,692

G

ribosomal protein L41

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL41 mRNA

NCBI chr 7:977,885...978,965

G

ribosomal protein L7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL7 mRNA

NCBI chr 5:8,000,446...8,003,454

G

ribosomal protein lateral stalk subunit P1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPLP1 mRNA

NCBI chr 8:71,289,539...71,290,872
Ensembl chr 8:62,393,177...62,395,339

G

ribonuclease P/MRP subunit p21

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPP21 mRNA

NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106

G

ribosomal protein S11

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS11 mRNA

NCBI chr 1:104,742,153...104,744,261
Ensembl chr 1:95,605,692...95,607,874

G

ribosomal protein S12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS12 mRNA

NCBI chr 1:23,499,943...23,502,234
Ensembl chr 1:21,680,852...21,683,014

G

ribosomal protein S19 binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS19BP1 mRNA

NCBI chr 7:111,809,354...111,812,741
Ensembl chr 7:111,809,355...111,812,757

G

ribosomal protein S2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS2 mRNA

NCBI chr10:14,251,841...14,253,697
Ensembl chr10:13,747,301...13,749,163

G

ribosomal protein S27

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27 mRNA

NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
Ensembl chr12:175,665,853...175,666,964

G

ribosomal protein S27a

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27A mRNA

NCBI chr14:107,486,664...107,488,941
Ensembl chr14:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011

G

ribosomal protein S6 kinase A5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA

NCBI chr 6:125,558,434...125,736,576
Ensembl chr 6:119,828,846...120,006,224

G

ribosomal protein S9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS9 mRNA

NCBI chr 1:74,427,084...74,430,513
Ensembl chr 1:65,511,723...65,515,123

G

R-spondin 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RSPO4 mRNA

NCBI chr 3:140,357,256...140,391,780
Ensembl chr 3:140,357,424...140,388,254

G

arginine and serine rich protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RSRP1 mRNA

NCBI chr 5:152,431,448...152,435,202
Ensembl chr 5:147,147,784...147,151,523

G

RT1 class I, locus CE16

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA

NCBI chr20:3,261,656...3,265,548
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus DOb

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-DOB mRNA

NCBI chr20:4,621,336...4,627,537
Ensembl chr20:4,619,816...4,625,667

G

reticulon 4 receptor-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RTN4RL1 mRNA

NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978

G

RWD domain containing 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RWDD1 mRNA

NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193

G

retinoid X receptor gamma

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of RXRG mRNA

NCBI chr13:82,276,330...82,318,097
Ensembl chr13:79,743,563...79,785,167

G

S100 calcium binding protein A6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of S100A6 mRNA

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of S100A8 mRNA

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:176,167,124...176,167,643

G

S100P binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of S100PBP mRNA

NCBI chr 5:141,494,352...141,535,752
Ensembl chr 5:141,494,353...141,535,525

G

sterile alpha motif domain containing 4A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMD4A mRNA

NCBI chr15:22,616,200...22,831,872
Ensembl chr15:20,134,377...20,348,380

G

SAMM50 sorting and assembly machinery component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMM50 mRNA

NCBI chr 7:117,197,460...117,221,668
Ensembl chr 7:115,317,404...115,341,682

G

store-operated calcium entry-associated regulatory factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA

NCBI chr16:64,720,404...64,738,653
Ensembl chr16:58,017,231...58,035,545

G

SREBF chaperone

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCAP mRNA

NCBI chr 8:119,184,366...119,239,086
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class F, member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCARF1 mRNA

NCBI chr10:60,359,213...60,371,516
Ensembl chr10:60,359,197...60,371,516

G

Scm polycomb group protein like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SCML1 mRNA

NCBI chr X:36,526,068...36,543,336
Ensembl chr X:32,894,327...32,911,366

G

sodium channel epithelial 1 subunit beta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCNN1B mRNA

NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:176,430,103...176,484,451

G

secernin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCRN2 mRNA

NCBI chr10:82,016,604...82,020,676
Ensembl chr10:82,016,649...82,020,675

G

stromal cell-derived factor 2-like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SDF2L1 mRNA

NCBI chr11:97,376,878...97,379,120
Ensembl chr11:83,872,659...83,874,902

G

succinate dehydrogenase complex assembly factor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SDHAF3 mRNA

NCBI chr 4:35,100,533...35,160,740
Ensembl chr 4:35,100,506...35,160,749

G

SEC11 homolog C, signal peptidase complex subunit

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC11C mRNA

NCBI chr18:61,590,905...61,607,247
Ensembl chr18:59,320,884...59,337,364

G

SEC31 homolog A, COPII coat complex component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC31A mRNA

NCBI chr14:9,518,655...9,573,579
Ensembl chr14:9,214,349...9,269,273

G

selenoprotein W

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SELENOW mRNA

NCBI chr 1:85,727,631...85,732,703
Ensembl chr 1:76,598,779...76,604,724
Ensembl chr 1:76,598,779...76,604,724

G

selectin P ligand

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SELPLG mRNA

NCBI chr12:48,457,102...48,470,444
Ensembl chr12:42,796,580...42,812,585

G

semaphorin 4A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEMA4A mRNA

NCBI chr 2:176,194,248...176,215,752
Ensembl chr 2:173,896,439...173,914,442

G

septin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEPTIN2 mRNA

NCBI chr 9:101,465,535...101,498,766
Ensembl chr 9:94,018,208...94,051,386

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERP2 mRNA

NCBI chr15:58,289,148...58,313,224
Ensembl chr15:51,879,877...51,904,785

G

serpin family E member 1

multiple interactions
decreases expression

EXP

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein
Hydralazine results in decreased expression of SERPINE1 mRNA

PMID:11318962 PMID:23415681

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657

G

serpin family G member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERPING1 mRNA

NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:69,842,739...69,852,034

G

SERTA domain containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERTAD2 mRNA

NCBI chr14:98,935,428...99,039,536
Ensembl chr14:94,733,579...94,838,313

G

splicing factor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SF1 mRNA

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:203,670,018...203,684,330

G

splicing factor 3B, subunit 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SF3B6 mRNA

NCBI chr 6:33,545,495...33,554,537
Ensembl chr 6:27,826,029...27,835,156

G

SH3 and multiple ankyrin repeat domains 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA

NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:199,169,429...199,589,394

G

shisa family member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

shortage in chiasmata 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHOC1 mRNA

NCBI chr 5:78,655,723...78,751,658
Ensembl chr 5:73,866,334...73,956,444

G

SHOX homeobox 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SHOX2 mRNA

NCBI chr 2:153,524,324...153,537,571
Ensembl chr 2:151,217,552...151,227,143

G

SID1 transmembrane family, member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SIDT2 mRNA

NCBI chr 8:55,129,091...55,146,446
Ensembl chr 8:46,232,383...46,248,700

G

signal-induced proliferation-associated 1 like 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SIPA1L1 mRNA

NCBI chr 6:107,570,569...107,849,613
Ensembl chr 6:101,839,404...102,116,950

G

Ski proto-oncogene

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SKI mRNA

NCBI chr 5:170,995,851...171,064,957
Ensembl chr 5:165,714,093...165,782,733

G

solute carrier family 12 member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC12A3 mRNA

NCBI chr19:10,636,594...10,690,008
Ensembl chr19:10,631,393...10,669,091

G

solute carrier family 16 member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC16A2 mRNA

NCBI chr X:72,791,096...72,914,299
Ensembl chr X:68,723,261...68,848,771

G

solute carrier family 17 member 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC17A9 mRNA

NCBI chr 3:188,211,106...188,233,553
Ensembl chr 3:167,839,385...167,855,985

G

solute carrier family 19 member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC19A2 mRNA

NCBI chr13:79,135,118...79,149,316
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 22 member 16

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A16 mRNA

NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019

G

solute carrier family 22, member 17

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A17 mRNA

NCBI chr15:32,352,273...32,358,780
Ensembl chr15:28,382,292...28,388,799

G

solute carrier family 22 member 2

multiple interactions

ISO

Hydralazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 23, member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC23A3 mRNA

NCBI chr 9:84,071,286...84,081,951
Ensembl chr 9:76,622,800...76,631,366

G

solute carrier family 25 member 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A13 mRNA

NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:34,179,224...34,361,902

G

solute carrier family 25 member 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A5 mRNA

NCBI chr X:120,897,616...120,900,683
Ensembl chr X:116,031,803...116,034,967

G

solute carrier family 2 member 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC2A9 mRNA

NCBI chr14:76,540,649...76,674,277
Ensembl chr14:72,328,320...72,461,981

G

solute carrier family 30 member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC30A2 mRNA

NCBI chr 5:151,843,451...151,855,674
Ensembl chr 5:146,559,733...146,571,956

G

solute carrier family 35 member C1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC35C1 mRNA

NCBI chr 3:78,421,925...78,429,603
Ensembl chr 3:78,421,933...78,428,520

G

solute carrier family 3 member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC3A2 mRNA

NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 6 member 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA

NCBI chr 4:156,211,381...156,248,491
Ensembl chr 4:154,540,468...154,576,152

G

solute carrier family 6 member 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA

NCBI chr19:30,183,289...30,228,292
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 8 member B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC8B1 mRNA

NCBI chr12:41,690,333...41,713,657
Ensembl chr12:36,029,760...36,053,031

G

SRA stem-loop interacting RNA binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLIRP mRNA

NCBI chr 6:112,819,684...112,828,715
Ensembl chr 6:107,088,403...107,097,791

G

SWI/SNF related BAF chromatin remodeling complex subunit C1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMARCC1 mRNA

NCBI chr 8:118,986,917...119,093,161
Ensembl chr 8:110,111,122...110,214,720

G

smoothened, frizzled class receptor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMO mRNA

NCBI chr 4:59,311,084...59,341,280
Ensembl chr 4:58,343,529...58,373,829

G

SMAD specific E3 ubiquitin protein ligase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMURF2 mRNA

NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488

G

snail family transcriptional repressor 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNAI3 mRNA

NCBI chr19:67,425,311...67,437,830
Ensembl chr19:50,516,771...50,523,486

G

SNF8 subunit of ESCRT-II

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNF8 mRNA

NCBI chr10:81,481,054...81,493,430
Ensembl chr10:80,984,363...80,996,734

G

small nuclear ribonucleoprotein U1 subunit 70

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRNP70 mRNA

NCBI chr 1:104,992,518...105,012,851
Ensembl chr 1:95,856,036...95,876,392

G

small nuclear ribonucleoprotein polypeptides B and B1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB mRNA

NCBI chr 3:137,824,870...137,832,479
Ensembl chr 3:117,370,100...117,379,339

G

small nuclear ribonucleoprotein polypeptide B2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB2 mRNA

NCBI chr 3:150,852,814...150,862,364
Ensembl chr 3:130,399,248...130,408,812

G

small nuclear ribonucleoprotein D2 polypeptide

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPD2 mRNA

NCBI chr 1:87,926,030...87,929,259
Ensembl chr 1:78,798,377...78,803,351
Ensembl chr20:78,798,377...78,803,351

G

small nuclear ribonucleoprotein polypeptide G

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPG mRNA

NCBI chr 4:120,369,676...120,377,263
Ensembl chr 4:118,812,252...118,819,826
Ensembl chr X:118,812,252...118,819,826

G

small nuclear ribonucleoprotein 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNU13 mRNA

NCBI chr 7:115,445,415...115,451,008
Ensembl chr 7:113,565,295...113,570,872
Ensembl chr 1:113,565,295...113,570,872

G

SRY-box transcription factor 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX1 mRNA

NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762

G

SRY-box transcription factor 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX9 mRNA

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:97,806,485...97,811,994

G

SAM pointed domain containing ets transcription factor

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPDEF mRNA

NCBI chr20:5,773,236...5,787,685
Ensembl chr20:5,771,441...5,785,893

G

serine peptidase inhibitor, Kunitz type 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPINT1 mRNA

NCBI chr 3:126,685,017...126,697,957
Ensembl chr 3:106,231,444...106,244,119

G

small proline-rich protein 1A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1A mRNA

NCBI chr 2:180,750,709...180,752,625
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1B mRNA

NCBI chr 2:180,704,457...180,706,355
Ensembl chr 2:178,009,130...178,009,567

G

splA/ryanodine receptor domain and SOCS box containing 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPSB2 mRNA

NCBI chr 4:159,298,362...159,301,568
Ensembl chr 4:157,613,401...157,615,284

G

signal recognition particle 72

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP72 mRNA

NCBI chr14:31,522,424...31,549,978
Ensembl chr14:31,168,293...31,195,729

G

signal recognition particle 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP9 mRNA

NCBI chr13:96,364,253...96,372,393
Ensembl chr13:93,832,580...93,840,720

G

SRSF protein kinase 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRPK3 mRNA

NCBI chr X:156,661,888...156,666,537
Ensembl chr X:151,510,539...151,515,198

G

sulfiredoxin 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:140,599,608...140,628,448

G

single stranded DNA binding protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSBP4 mRNA

NCBI chr16:18,828,014...18,838,941
Ensembl chr16:18,828,054...18,838,947

G

sarcospan

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA

NCBI chr 4:180,620,762...180,666,893
Ensembl chr 4:178,897,147...178,931,554

G

signal sequence receptor subunit 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSR1 mRNA

NCBI chr17:27,039,203...27,067,352
Ensembl chr17:26,833,741...26,861,821

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ST8SIA2 mRNA

NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091

G

stabilin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STAB2 mRNA

NCBI chr 7:23,136,938...23,342,633
Ensembl chr 7:21,249,391...21,434,042

G

STAG1 cohesin complex component

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STAG1 mRNA

NCBI chr 8:110,057,981...110,443,666
Ensembl chr 8:101,179,039...101,564,677

G

STEAP2 metalloreductase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of STEAP2 mRNA

NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791

G

serine/threonine kinase 38

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STK38 mRNA

NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,034,242...7,068,198

G

syntaxin 11

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STX11 mRNA

NCBI chr 1:9,111,216...9,140,227
Ensembl chr 1:7,289,976...7,320,164

G

syntaxin 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STX5 mRNA

NCBI chr 1:215,066,532...215,082,685
Ensembl chr 1:205,637,413...205,653,563

G

serine/threonine/tyrosine interacting protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of STYX mRNA

NCBI chr15:18,565,214...18,595,797
Ensembl chr15:18,564,633...18,593,524

G

SUFU negative regulator of hedgehog signaling

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SUFU mRNA

NCBI chr 1:255,199,108...255,296,983
Ensembl chr 1:245,257,768...245,355,577

G

small ubiquitin-like modifier 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SUMO3 mRNA

NCBI chr20:11,009,730...11,020,502
Ensembl chr20:11,007,148...11,020,877
Ensembl chr20:11,007,148...11,020,877

G

synaptophysin

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SYP mRNA

NCBI chr X:17,521,348...17,536,449
Ensembl chr X:14,849,444...14,864,745

G

synaptotagmin 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of SYT6 mRNA

NCBI chr 2:193,781,051...193,840,741
Ensembl chr 2:191,093,007...191,149,956

G

transforming, acidic coiled-coil containing protein 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TACC2 mRNA

NCBI chr 1:194,546,428...194,758,152
Ensembl chr 1:185,116,111...185,327,881

G

TATA-box binding protein associated factor 12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TAF12 mRNA

NCBI chr 5:149,756,826...149,772,886
Ensembl chr 5:144,472,841...144,488,849

G

TAFA chemokine like family member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TAFA1 mRNA

NCBI chr 4:128,738,028...129,244,223
Ensembl chr 4:128,739,313...129,243,777

G

transaldolase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TALDO1 mRNA

NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974

G

TBC1 domain family member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBC1D1 mRNA

NCBI chr14:44,289,241...44,489,246
Ensembl chr14:43,935,636...44,136,499

G

tubulin folding cofactor D

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBCD mRNA

NCBI chr10:107,215,626...107,372,398
Ensembl chr10:106,717,367...106,874,122

G

transforming growth factor beta regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBRG1 mRNA

NCBI chr 8:37,355,274...37,362,933
Ensembl chr 8:37,354,658...37,362,930

G

T-box transcription factor 18

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBX18 mRNA

NCBI chr 8:88,652,054...88,680,081
Ensembl chr 8:88,652,054...88,680,058

G

transcription elongation regulator 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TCERG1 mRNA

NCBI chr18:34,756,558...34,817,441
Ensembl chr18:34,505,751...34,566,470

G

transcription factor 12

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TCF12 mRNA

NCBI chr 8:81,371,201...81,682,337
Ensembl chr 8:72,492,567...72,799,201

G

tec protein tyrosine kinase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TEC mRNA

NCBI chr14:35,706,557...35,815,563
Ensembl chr14:35,352,829...35,461,557

G

terminal nucleotidyltransferase 5A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TENT5A mRNA

NCBI chr 8:95,102,349...95,109,100
Ensembl chr 8:86,225,357...86,229,045

G

transcription factor CP2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFCP2 mRNA

NCBI chr 7:131,616,777...131,658,995
Ensembl chr 7:131,616,785...131,658,939

G

transcription factor Dp-1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFDP1 mRNA

NCBI chr16:82,864,220...82,903,166
Ensembl chr16:76,162,043...76,200,817

G

trefoil factor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFF2 mRNA

NCBI chr20:9,217,110...9,220,979
Ensembl chr20:9,215,761...9,219,619

G

TGFB-induced factor homeobox 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TGIF2 mRNA

NCBI chr 3:165,791,101...165,808,669
Ensembl chr 3:145,333,418...145,348,596
Ensembl chr17:145,333,418...145,348,596

G

thrombomodulin

multiple interactions

EXP

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:135,862,835...135,867,193

G

thioesterase superfamily member 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

thyroid hormone receptor associated protein 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of THRAP3 mRNA

NCBI chr 5:143,729,821...143,772,105
Ensembl chr 5:138,445,295...138,487,477

G

Thy-1 cell surface antigen

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of THY1 mRNA

NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:44,389,513...44,394,659

G

translocase of inner mitochondrial membrane 13

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM13 mRNA

NCBI chr 7:9,459,490...9,460,849
Ensembl chr 7:8,809,058...8,809,910

G

translocase of inner mitochondrial membrane 50

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM50 mRNA

NCBI chr 1:92,702,437...92,710,311
Ensembl chr 1:83,556,757...83,582,793

G

translocase of inner mitochondrial membrane 8 homolog B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM8B mRNA

NCBI chr 8:59,850,737...59,852,117
Ensembl chr 8:50,954,342...50,955,729

G

TIMP metallopeptidase inhibitor 1

decreases expression

EXP

hydralazine decreases expression of Timp1 protein in blood serum

RGD

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMP2 mRNA

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:103,531,505...103,590,611

G

TOR signaling pathway regulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIPRL mRNA

NCBI chr13:77,527,176...77,552,026
Ensembl chr13:77,527,176...77,552,074

G

TLE family member 5, transcriptional modulator

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TLE5 mRNA

NCBI chr 7:8,794,123...8,801,056
Ensembl chr 7:8,143,357...8,150,113

G

transmembrane 7 superfamily member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TM7SF3 mRNA

NCBI chr 4:181,248,819...181,280,844
Ensembl chr 4:179,518,130...179,550,154

G

translation machinery associated 7 homolog

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMA7 mRNA

NCBI chr 8:109,726,213...109,730,902
Ensembl chr 8:109,726,196...109,735,474

G

transmembrane and coiled-coil domains 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMCO1 mRNA

NCBI chr13:81,993,172...82,016,496
Ensembl chr13:79,460,135...79,483,555

G

transmembrane p24 trafficking protein 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMED3 mRNA

NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:90,241,516...90,249,346

G

transmembrane protein 248

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM248 mRNA

NCBI chr12:32,069,113...32,093,380
Ensembl chr12:26,432,953...26,457,105

G

transmembrane protein 260

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM260 mRNA

NCBI chr15:21,734,119...21,804,049
Ensembl chr15:21,734,151...21,806,801

G

transmembrane protein 80

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM80 mRNA

NCBI chr 1:196,435,999...196,444,368
Ensembl chr 1:196,436,003...196,444,367
Ensembl chr 1:196,436,003...196,444,367

G

transmembrane protein 9

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM9 mRNA

NCBI chr13:47,458,486...47,475,832
Ensembl chr13:47,458,498...47,475,832

G

thymosin, beta 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMSB10 mRNA

NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028

G

tumor necrosis factor

decreases secretion
increases expression
multiple interactions

ISO
EXP

Hydralazine results in decreased secretion of TNF protein
Hydralazine results in increased expression of TNF mRNA
Vehicle Emissions inhibits the reaction [Hydralazine results in increased expression of TNF mRNA]

PMID:16612254 PMID:23415681

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 8

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TNFAIP8 mRNA

NCBI chr18:45,370,334...45,486,036
Ensembl chr18:43,183,916...43,299,517

G

translocase of outer mitochondrial membrane 20

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM20 mRNA

NCBI chr19:71,822,429...71,832,420
Ensembl chr19:54,923,402...54,935,198

G

translocase of outer mitochondrial membrane 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM7 mRNA

NCBI chr 4:11,305,122...11,311,963
Ensembl chr 4:11,305,110...11,311,962

G

DNA topoisomerase II binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of TOPBP1 mRNA

NCBI chr 8:112,766,791...112,815,203
Ensembl chr 8:103,887,865...103,931,674

G

tumor protein p53

multiple interactions
increases activity

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TP53 mRNA
Hydralazine results in increased activity of TP53 protein

PMID:12082016 PMID:17183730

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TPI1 mRNA

NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541

G

tropomyosin 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TPM2 mRNA

NCBI chr 5:62,566,712...62,576,066
Ensembl chr 5:57,770,864...57,779,992

G

tryptase alpha/beta 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TPSAB1 mRNA

NCBI chr10:14,864,887...14,867,302
Ensembl chr10:14,360,396...14,362,811

G

transmembrane phosphoinositide 3-phosphatase and tensin homolog 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TPTE2 mRNA

NCBI chr16:69,658,874...69,756,571
Ensembl chr16:69,658,875...69,752,949

G

Tnf receptor-associated factor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAF2 mRNA

NCBI chr 3:28,740,098...28,764,752
Ensembl chr 3:8,341,951...8,366,538

G

trafficking protein particle complex subunit 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC4 mRNA

NCBI chr 8:53,626,382...53,630,042
Ensembl chr 8:44,725,331...44,733,491

G

trafficking protein particle complex subunit 6A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC6A mRNA

NCBI chr 1:88,286,533...88,293,493
Ensembl chr 1:79,158,529...79,165,493

G

tribbles pseudokinase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIB2 mRNA

NCBI chr 6:44,274,762...44,299,139
Ensembl chr 6:38,545,975...38,569,370

G

tripartite motif-containing 46

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIM46 mRNA

NCBI chr 2:176,939,253...176,952,285
Ensembl chr 2:174,641,496...174,654,141

G

thyroid hormone receptor interactor 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP10 mRNA

NCBI chr 9:2,133,085...2,147,795
Ensembl chr 9:2,133,671...2,147,799

G

thyroid hormone receptor interactor 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP6 mRNA

NCBI chr12:25,022,959...25,027,366
Ensembl chr12:19,386,014...19,390,618

G

tRNA phosphotransferase 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TRPT1 mRNA

NCBI chr 1:204,186,295...204,191,294
Ensembl chr 1:204,186,295...204,191,294

G

tRNA splicing endonuclease subunit 54

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TSEN54 mRNA

NCBI chr10:101,540,479...101,549,022
Ensembl chr10:101,042,503...101,050,087

G

tetraspanin 10

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN10 mRNA

NCBI chr10:105,715,803...105,721,503
Ensembl chr10:105,715,961...105,719,813

G

tetraspanin 18

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN18 mRNA

NCBI chr 3:99,615,465...99,755,270
Ensembl chr 3:79,161,662...79,299,852

G

translocator protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPO mRNA

NCBI chr 7:116,600,214...116,610,461
Ensembl chr 7:114,720,188...114,730,450

G

thiosulfate sulfurtransferase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TST mRNA

NCBI chr 7:111,828,557...111,836,980
Ensembl chr 7:109,948,062...109,957,216

G

tubulin, beta 6 class V

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TUBB6 mRNA

NCBI chr18:63,213,287...63,222,926
Ensembl chr18:60,943,375...60,954,418

G

tRNA-yW synthesizing protein 3 homolog

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of TYW3 mRNA

NCBI chr 2:246,189,627...246,211,737
Ensembl chr 2:243,529,946...243,552,039

G

ubiquitin A-52 residue ribosomal protein fusion product 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UBA52 mRNA

NCBI chr16:18,952,583...18,954,780
Ensembl chr16:18,900,616...18,920,807

G

ubiquitin-conjugating enzyme E2L 6

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UBE2L6 mRNA

NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048

G

U-box domain containing 5

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of UBOX5 mRNA

NCBI chr 3:138,259,311...138,300,807
Ensembl chr 3:117,807,092...117,847,722

G

UBX domain protein 11

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UBXN11 mRNA

NCBI chr 5:151,613,411...151,637,274
Ensembl chr 5:146,329,842...146,353,526

G

UBX domain protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UBXD2 mRNA

NCBI chr13:42,292,346...42,324,928
Ensembl chr13:39,740,107...39,772,491

G

UDP-glucose glycoprotein glucosyltransferase 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UGGT2 mRNA

NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806

G

UL16 binding protein 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ULBP1 mRNA

NCBI chr 1:3,506,106...3,527,982

G

unc-45 myosin chaperone A

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UNC45A mRNA

NCBI chr 1:143,691,183...143,705,944
Ensembl chr 1:134,281,933...134,301,586

G

ubiquinol-cytochrome c reductase complex assembly factor 2

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCC2 mRNA

NCBI chr20:5,204,682...5,217,080
Ensembl chr20:5,202,837...5,214,164
Ensembl chr17:5,202,837...5,214,164

G

ubiquinol-cytochrome c reductase binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCRB mRNA

NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150

G

ubiquinol-cytochrome c reductase, complex III subunit VII

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCRQ mRNA

NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169

G

upstream transcription factor family member 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of USF3 mRNA

NCBI chr11:56,470,738...56,529,736
Ensembl chr11:56,476,122...56,529,884

G

ubiquitin specific peptidase 33

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of USP33 mRNA

NCBI chr 2:243,938,958...243,988,424
Ensembl chr 2:241,292,985...241,328,479

G

ubiquitin specific peptidase 40

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of USP40 mRNA

NCBI chr 9:88,607,920...88,678,940
Ensembl chr 9:88,607,930...88,678,914

G

ubiquitin specific peptidase 49

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of USP49 mRNA

NCBI chr 9:20,803,177...20,867,681
Ensembl chr 9:13,308,178...13,366,132

G

vascular endothelial growth factor B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of VEGFB mRNA

NCBI chr 1:213,601,570...213,607,254
Ensembl chr 1:204,172,225...204,177,944

G

WBP2 N-terminal like

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of WBP2NL mRNA

NCBI chr 7:115,694,910...115,710,912
Ensembl chr 7:113,814,992...113,831,333

G

WW domain binding protein 4

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of WBP4 mRNA

NCBI chr15:61,271,774...61,299,740
Ensembl chr15:54,862,843...54,890,647

G

WD repeat domain 46

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of WDR46 mRNA

NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535

G

Wnt family member 1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of WNT1 mRNA

NCBI chr 7:131,817,558...131,821,605
Ensembl chr 7:129,938,604...129,942,651

G

xylulokinase

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of XYLB mRNA

NCBI chr 8:119,093,466...119,128,858
Ensembl chr 8:119,096,029...119,128,848

G

YTH N6-methyladenosine RNA binding protein F1

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of YTHDF1 mRNA

NCBI chr 3:188,402,228...188,417,740
Ensembl chr 3:168,024,663...168,040,172

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of YWHAQ mRNA

NCBI chr 6:46,664,358...46,694,875
Ensembl chr 6:40,935,949...40,966,273

G

zinc finger CCCH type containing 3

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZC3H3 mRNA

NCBI chr 7:109,321,423...109,406,241
Ensembl chr 7:107,440,694...107,525,451

G

zinc finger DHHC-type palmitoyltransferase 17

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZDHHC17 mRNA

NCBI chr 7:46,369,963...46,433,691
Ensembl chr 7:46,369,988...46,433,764

G

zinc finger DHHC-type palmitoyltransferase 7

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZDHHC7 mRNA

NCBI chr19:65,048,140...65,065,286
Ensembl chr19:48,139,527...48,156,673

G

zinc finger AN1-type containing 2B

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFAND2B mRNA

NCBI chr 9:84,114,170...84,117,115
Ensembl chr 9:76,665,546...76,668,445

G

zinc finger protein 18

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ZNF18 mRNA

NCBI chr10:50,473,428...50,495,707
Ensembl chr10:50,473,483...50,495,706

G

zinc finger protein 354C

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF354C mRNA

NCBI chr10:35,630,738...35,647,176
Ensembl chr10:35,132,959...35,145,661

G

zinc finger protein 386 (Kruppel-like)

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF519 mRNA

NCBI chr 6:143,109,563...143,124,266
Ensembl chr 6:136,966,586...136,983,441

G

zinc finger protein 398

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF398 mRNA

NCBI chr 4:76,849,672...76,881,075
Ensembl chr 4:76,849,681...76,876,243

G

zinc finger protein 592

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF592 mRNA

NCBI chr 1:134,951,286...135,002,443
Ensembl chr 1:134,967,783...135,002,443

G

zinc finger protein 62

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFP62 mRNA

NCBI chr10:34,019,367...34,040,564
Ensembl chr10:33,500,323...33,542,013

G

zinc finger protein 622

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF622 mRNA

NCBI chr 2:76,479,605...76,494,405
Ensembl chr 2:76,335,609...76,493,898

G

zinc finger protein 768

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF768 mRNA

NCBI chr 1:181,966,314...181,968,950
Ensembl chr 1:181,966,316...181,969,147

G

zinc finger protein 873

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF441 mRNA

NCBI chr 7:7,926,951...7,959,822
Ensembl chr 7:7,926,957...7,951,803

G

zinc finger protein 94

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF45 mRNA

NCBI chr 1:79,858,188...79,879,702
Ensembl chr 1:79,859,180...79,879,612

G

zinc finger RNA binding protein

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFR mRNA

NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322

G

zinc metallopeptidase STE24

multiple interactions

ISO

[Hydralazine co-treated with Valproic Acid] results in increased expression of ZMPSTE24 mRNA

NCBI chr 5:139,912,395...139,945,532
Ensembl chr 5:134,627,229...134,660,110

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of ACACB mRNA

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA oxidase 1

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of ACOX1 mRNA

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,406,197...101,431,232

G

actin alpha 2, smooth muscle

multiple interactions

ISO

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

adhesion G protein-coupled receptor E1

multiple interactions

ISO

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 mRNA]

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,242,474...2,398,000

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

ISO

olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of AIFM1 protein]

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions

ISO

olaparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

BRCA1 associated deubiquitinase 1

increases response to substance

ISO

BAP1 gene mutant form results in increased susceptibility to olaparib

NCBI chr16:6,453,126...6,461,952
Ensembl chr16:6,446,709...6,455,535

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

ISO

olaparib results in increased expression of BAX protein
INCB054329 promotes the reaction [olaparib results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

ISO

olaparib results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

olaparib results in decreased expression of BIRC5 protein

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

BRCA1, DNA repair associated

affects response to substance
multiple interactions

ISO

BRCA1 affects the susceptibility to olaparib
[BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [olaparib co-treated with INCB054329] results in decreased expression of BRCA1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of BRCA1 protein]

PMID:21633166 PMID:29567272

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

affects response to substance

ISO

BRCA2 affects the susceptibility to olaparib

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:59,819...100,567

G

bromodomain containing 4

affects response to substance
multiple interactions

ISO

BRD4 protein affects the susceptibility to olaparib
[BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein

NCBI chr 7:11,866,997...11,946,575
Ensembl chr 7:11,216,446...11,295,539

G

caspase 3

multiple interactions

ISO

[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein]; CASP3 protein affects the reaction [CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of CASP3 protein]

PMID:25531448 PMID:26544897 PMID:35396826 PMID:38493911

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

ISO

[CRABP2 protein affects the susceptibility to olaparib] which affects the expression of and affects the cleavage of CASP8 protein; [Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone affects the reaction [CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein]; CASP3 protein affects the reaction [CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]; olaparib results in decreased expression of and results in increased cleavage of CASP8 protein

PMID:25531448 PMID:26544897 PMID:38493911

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

ISO

[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CASP9 protein]

PMID:25531448 PMID:35396826

Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

multiple interactions

ISO

olaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226

G

cellular communication network factor 2

multiple interactions

ISO

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734

G

cyclin E1

multiple interactions

ISO

[olaparib co-treated with INCB054329] results in decreased expression of CCNE1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of CCNE1 protein]

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 2

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO

INCB054329 promotes the reaction [olaparib results in increased expression of CDKN1A protein]; olaparib promotes the reaction [INCB054329 results in increased expression of CDKN1A protein]

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

checkpoint kinase 1

increases phosphorylation

ISO

olaparib results in increased phosphorylation of CHEK1 protein

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:36,420,569...36,441,009

G

collagen type I alpha 1 chain

multiple interactions

ISO

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624

G

cellular retinoic acid binding protein 2

affects response to substance
multiple interactions

ISO

CRABP2 protein affects the susceptibility to olaparib
[CRABP2 protein affects the susceptibility to olaparib] which affects the expression of and affects the cleavage of CASP8 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone affects the reaction [CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]]; CASP3 protein affects the reaction [CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]]; CRABP2 protein affects the reaction [olaparib results in increased cleavage of CASP8 protein]

NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:173,416,857...173,421,379

G

CCCTC-binding factor

decreases binding

ISO

olaparib decreases binding of CTCF to Cp promoter region in human lymphoblastoid cell lines

RGD

NCBI chr19:50,431,478...50,481,013
Ensembl chr19:33,529,319...33,571,123

G

C-X-C motif chemokine ligand 2

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CXCL2 mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CXCL2 mRNA]

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075

G

cytochrome c, somatic

multiple interactions

ISO

olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CYCS protein]

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO

olaparib results in increased expression of DDIT3 protein
DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

fatty acid synthase

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

fumarate hydratase

increases response to substance

ISO

FH mutant form results in increased susceptibility to olaparib

NCBI chr13:90,056,565...90,082,450
Ensembl chr13:87,524,337...87,550,266

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of GPT protein; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

H2A.X variant histone

multiple interactions
increases expression
increases phosphorylation

ISO

(+)-JQ1 compound promotes the reaction [olaparib results in increased expression of H2AX protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein; [Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]; INCB054329 promotes the reaction [olaparib results in increased expression of H2AX protein]; olaparib promotes the reaction [(+)-JQ1 compound results in increased expression of H2AX protein]; olaparib promotes the reaction [INCB054329 results in increased expression of H2AX protein]; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of H2AX protein

PMID:25531448 PMID:26544897 PMID:29567272

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

high mobility group box 1

multiple interactions

EXP

olaparib inhibits the reaction [Ethanol results in increased expression of HMGB1 protein]

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

intercellular adhesion molecule 1

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ISO

olaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO
EXP

Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]
bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]

PMID:34826546 PMID:36639873

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

marker of proliferation Ki-67

decreases expression
multiple interactions

ISO

olaparib results in decreased expression of MKI67 protein
INCB054329 promotes the reaction [olaparib results in decreased expression of MKI67 protein]; olaparib promotes the reaction [INCB054329 results in decreased expression of MKI67 protein]

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762

G

mutL homolog 1

multiple interactions

ISO

olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine]

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:111,196,468...111,233,617

G

myeloperoxidase

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of MPO protein

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819

G

mutS homolog 2

multiple interactions

ISO

olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine]

NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:6,813,795...6,872,938

G

mutS homolog 3

decreases response to substance

ISO

MSH3 protein results in decreased susceptibility to olaparib

NCBI chr 2:25,179,400...25,320,857

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity
decreases binding
increases cleavage

ISO

olaparib inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]
olaparib results in decreased activity of PARP1 protein
olaparib decreases binding of PARP1 to Cp promoter region in human lymphoblastoid cell lines
(+)-JQ1 compound promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; INCB054329 promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of PARP1 protein]; olaparib promotes the reaction [INCB054329 results in increased cleavage of PARP1 protein]

CTD
RGD

PMID:24814482 PMID:28001384 PMID:29567272 PMID:35396826 PMID:29976663

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

multiple interactions

ISO

olaparib binds to and results in decreased activity of PARP2 protein

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

proliferating cell nuclear antigen

decreases expression
multiple interactions

ISO

olaparib results in decreased expression of PCNA protein
INCB054329 promotes the reaction [olaparib results in decreased expression of PCNA protein]

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

phospholipase A2 group IIA

multiple interactions

EXP

olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G2A protein]

NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group 4A

multiple interactions

EXP

olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G4A protein]

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of PPARA mRNA

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346

G

RAD51 recombinase

multiple interactions

ISO

[olaparib co-treated with INCB054329] results in decreased expression of RAD51 protein

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:106,100,381...106,125,035

G

succinate dehydrogenase complex iron sulfur subunit B

increases response to substance

ISO

SDHB mutant form results in increased susceptibility to olaparib

NCBI chr 5:158,547,775...158,568,589
Ensembl chr 5:153,264,899...153,314,293

G

sirtuin 1

increases expression
multiple interactions

ISO

olaparib results in increased expression of SIRT1 protein
olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260

G

sequestosome 1

multiple interactions

EXP

olaparib inhibits the reaction [Hydrogen Peroxide results in decreased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

[Dietary Fats co-treated with olaparib] results in decreased expression of SREBF1 mRNA

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor, beta 1

multiple interactions

ISO

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

ISO

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of TNF mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; olaparib inhibits the reaction [Ethanol results in increased expression of TNF protein]

PMID:27984176 PMID:29317476

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

multiple interactions

ISO

[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]

NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135

G

tumor protein p53

multiple interactions
increases phosphorylation

ISO

[Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of TP53 protein

PMID:25531448 PMID:26544897

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

X-ray repair cross complementing 1

multiple interactions

ISO

olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:80,141,207...80,168,701

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

multiple interactions

EXP

phthalazine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[vatalanib co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

ISO

[vatalanib co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; vatalanib inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19887
chemical entity	19885
atom	19885
nonmetal atom	19809
nitrogen atom	18982
nitrogen molecular entity	18982
organonitrogen compound	18834
organonitrogen heterocyclic compound	18154
phthalazines	823
(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid	16
(R)-6-(4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile	0
1-(1-piperidinyl)-2-[[4-(prop-2-enylamino)-1-phthalazinyl]thio]ethanone	0
1-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)-2-(1-phthalazinyloxy)ethanone	0
2-(1,3-benzothiazol-2-yl)-3-(1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl)-5-[(E)-2-phenylethenyl]-2H-tetrazol-3-ium	0
2-(1,4-dioxo-3H-phthalazin-2-yl)-N-(5-methyl-4-phenyl-2-thiazolyl)acetamide	0
2-(4-chlorophenyl)-1-phthalazinone	0
2-(4-methyl-1-oxo-2-phthalazinyl)-N-(4-methylphenyl)acetamide	0
2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid	0
2-[[4-(2-chlorophenyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1-phthalazinone	0
2-methyl-1,2-dihydrophthalazin-1-one	0
3-(1-phthalazinylhydrazo)-2-indolone	0
3-(4-chlorophenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxylic acid	0
3-(4-nitrophenyl)-2H-phthalazine-1,4-dione	0
3-ethyl-4-oxo-1-phthalazinecarboxylic acid [2-(1H-indol-3-yl)-2-oxoethyl] ester	0
3-ethyl-4-oxo-1-phthalazinecarboxylic acid [2-[2-(2,4-dioxo-3-thiazolidinyl)ethylamino]-2-oxoethyl] ester	0
3-methyl-4-oxo-1-phthalazinecarboxylic acid [2-(7-ethyl-1H-indol-3-yl)-2-oxoethyl] ester	0
4-(6-fluoro-3-methyl-4-oxo-1-benzopyran-2-yl)-2-methyl-1-phthalazinone	0
4-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-2-methyl-1-phthalazinone	0
4-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-oxomethyl]-2-ethyl-1-phthalazinone	0
4-[[4-(benzenesulfonyl)-1-piperazinyl]-oxomethyl]-2-methyl-1-phthalazinone	0
4-methyl-2-(2-naphthalenyl)-1-phthalazinone	0
4-methyl-2-(8-quinolinyl)-1-phthalazinone	0
4-methyl-N-prop-2-enyl-1-phthalazinamine	0
4-oxo-3-phenyl-1-phthalazinecarboxylic acid [2-[(1,1-dioxo-3-thiolanyl)amino]-2-oxoethyl] ester	0
4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide	0
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide	0
ABEI	0
Amycophthalazinone A	0
Desmethylazelastine	1
Hydralazine acetone hydrazone	0
Hydralazine pyruvate hydrazone	0
N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine	0
N-(1-phthalazinylamino)carbamic acid ethyl ester	0
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide	0
N-(2,6-dimethoxyphenyl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide	0
N-(2-furanylmethyl)-3-(2-methoxyphenyl)-4-oxo-1-phthalazinecarboxamide	0
N-(2-oxolanylmethyl)-2-[1-oxo-4-(3-pyridinylmethyl)-2-phthalazinyl]acetamide	0
Phthalazinone pyrazole	0
Vatalanib dihydrochloride	0
azelastine +	8
budralazine	0
dihydralazine	1
hydralazine +	755
olaparib	59
oxagrelate	0
phthalazin-1(2H)-one	0
phthalazine	1
picodralazine	0
talastine	0
vatalanib +	2
Path 2
Term	Annotations
CHEBI ontology	19887
subatomic particle	19885
composite particle	19885
hadron	19885
baryon	19885
nucleon	19885
atomic nucleus	19885
atom	19885
main group element atom	19824
p-block element atom	19824
p-block molecular entity	19824
carbon group molecular entity	19763
organic molecular entity	19760
organic molecule	19713
organic cyclic compound	19505
organic heterocyclic compound	18875
organic heteropolycyclic compound	18302
organic heterobicyclic compound	17242
phthalazines	823
(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid	16
(R)-6-(4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile	0
1-(1-piperidinyl)-2-[[4-(prop-2-enylamino)-1-phthalazinyl]thio]ethanone	0
1-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)-2-(1-phthalazinyloxy)ethanone	0
2-(1,3-benzothiazol-2-yl)-3-(1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl)-5-[(E)-2-phenylethenyl]-2H-tetrazol-3-ium	0
2-(1,4-dioxo-3H-phthalazin-2-yl)-N-(5-methyl-4-phenyl-2-thiazolyl)acetamide	0
2-(4-chlorophenyl)-1-phthalazinone	0
2-(4-methyl-1-oxo-2-phthalazinyl)-N-(4-methylphenyl)acetamide	0
2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid	0
2-[[4-(2-chlorophenyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]methyl]-1-phthalazinone	0
2-methyl-1,2-dihydrophthalazin-1-one	0
3-(1-phthalazinylhydrazo)-2-indolone	0
3-(4-chlorophenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxylic acid	0
3-(4-nitrophenyl)-2H-phthalazine-1,4-dione	0
3-ethyl-4-oxo-1-phthalazinecarboxylic acid [2-(1H-indol-3-yl)-2-oxoethyl] ester	0
3-ethyl-4-oxo-1-phthalazinecarboxylic acid [2-[2-(2,4-dioxo-3-thiazolidinyl)ethylamino]-2-oxoethyl] ester	0
3-methyl-4-oxo-1-phthalazinecarboxylic acid [2-(7-ethyl-1H-indol-3-yl)-2-oxoethyl] ester	0
4-(6-fluoro-3-methyl-4-oxo-1-benzopyran-2-yl)-2-methyl-1-phthalazinone	0
4-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-2-methyl-1-phthalazinone	0
4-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-oxomethyl]-2-ethyl-1-phthalazinone	0
4-[[4-(benzenesulfonyl)-1-piperazinyl]-oxomethyl]-2-methyl-1-phthalazinone	0
4-methyl-2-(2-naphthalenyl)-1-phthalazinone	0
4-methyl-2-(8-quinolinyl)-1-phthalazinone	0
4-methyl-N-prop-2-enyl-1-phthalazinamine	0
4-oxo-3-phenyl-1-phthalazinecarboxylic acid [2-[(1,1-dioxo-3-thiolanyl)amino]-2-oxoethyl] ester	0
4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide	0
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide	0
ABEI	0
Amycophthalazinone A	0
Desmethylazelastine	1
Hydralazine acetone hydrazone	0
Hydralazine pyruvate hydrazone	0
N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine	0
N-(1-phthalazinylamino)carbamic acid ethyl ester	0
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide	0
N-(2,6-dimethoxyphenyl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide	0
N-(2-furanylmethyl)-3-(2-methoxyphenyl)-4-oxo-1-phthalazinecarboxamide	0
N-(2-oxolanylmethyl)-2-[1-oxo-4-(3-pyridinylmethyl)-2-phthalazinyl]acetamide	0
Phthalazinone pyrazole	0
Vatalanib dihydrochloride	0
azelastine +	8
budralazine	0
dihydralazine	1
hydralazine +	755
olaparib	59
oxagrelate	0
phthalazin-1(2H)-one	0
phthalazine	1
picodralazine	0
talastine	0
vatalanib +	2

paths to the root